1
|
Al Tabosh T, Liu H, Koça D, Al Tarrass M, Tu L, Giraud S, Delagrange L, Beaudoin M, Rivière S, Grobost V, Rondeau-Lutz M, Dupuis O, Ricard N, Tillet E, Machillot P, Salomon A, Picart C, Battail C, Dupuis-Girod S, Guignabert C, Desroches-Castan A, Bailly S. Impact of heterozygous ALK1 mutations on the transcriptomic response to BMP9 and BMP10 in endothelial cells from hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension donors. Angiogenesis 2024; 27:211-227. [PMID: 38294582 PMCID: PMC11021321 DOI: 10.1007/s10456-023-09902-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2023] [Accepted: 12/03/2023] [Indexed: 02/01/2024]
Abstract
Heterozygous activin receptor-like kinase 1 (ALK1) mutations are associated with two vascular diseases: hereditary hemorrhagic telangiectasia (HHT) and more rarely pulmonary arterial hypertension (PAH). Here, we aimed to understand the impact of ALK1 mutations on BMP9 and BMP10 transcriptomic responses in endothelial cells. Endothelial colony-forming cells (ECFCs) and microvascular endothelial cells (HMVECs) carrying loss of function ALK1 mutations were isolated from newborn HHT and adult PAH donors, respectively. RNA-sequencing was performed on each type of cells compared to controls following an 18 h stimulation with BMP9 or BMP10. In control ECFCs, BMP9 and BMP10 stimulations induced similar transcriptomic responses with around 800 differentially expressed genes (DEGs). ALK1-mutated ECFCs unexpectedly revealed highly similar transcriptomic profiles to controls, both at the baseline and upon stimulation, and normal activation of Smad1/5 that could not be explained by a compensation in cell-surface ALK1 level. Conversely, PAH HMVECs revealed strong transcriptional dysregulations compared to controls with > 1200 DEGs at the baseline. Consequently, because our study involved two variables, ALK1 genotype and BMP stimulation, we performed two-factor differential expression analysis and identified 44 BMP9-dysregulated genes in mutated HMVECs, but none in ECFCs. Yet, the impaired regulation of at least one hit, namely lunatic fringe (LFNG), was validated by RT-qPCR in three different ALK1-mutated endothelial models. In conclusion, ALK1 heterozygosity only modified the BMP9/BMP10 regulation of few genes, including LFNG involved in NOTCH signaling. Future studies will uncover whether dysregulations in such hits are enough to promote HHT/PAH pathogenesis, making them potential therapeutic targets, or if second hits are necessary.
Collapse
Affiliation(s)
- T Al Tabosh
- Biosanté unit U1292, Grenoble Alpes University, INSERM, CEA, 38000, Grenoble, France
| | - H Liu
- Biosanté unit U1292, Grenoble Alpes University, INSERM, CEA, 38000, Grenoble, France
| | - D Koça
- Biosanté unit U1292, Grenoble Alpes University, INSERM, CEA, 38000, Grenoble, France
| | - M Al Tarrass
- Biosanté unit U1292, Grenoble Alpes University, INSERM, CEA, 38000, Grenoble, France
| | - L Tu
- Faculté de Médecine, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Université Paris-Saclay, 94276, Le Kremlin-Bicêtre, France
- INSERM UMR_S 999 «Pulmonary Hypertension: Pathophysiology and Novel Therapies», Hôpital Marie Lannelongue, 92350, Le Plessis-Robinson, France
| | - S Giraud
- Genetics Department, Femme-Mère-Enfants Hospital, Hospices Civils de Lyon, 69677, Bron, France
| | - L Delagrange
- Genetics Department, Femme-Mère-Enfants Hospital, Hospices Civils de Lyon, 69677, Bron, France
- National Reference Center for HHT, 69677, Bron, France
| | - M Beaudoin
- Genetics Department, Femme-Mère-Enfants Hospital, Hospices Civils de Lyon, 69677, Bron, France
- National Reference Center for HHT, 69677, Bron, France
| | - S Rivière
- Internal Medicine Department, CHU of Montpellier, St Eloi Hospital and Center of Clinical Investigation, INSERM, CIC 1411, 34295, Montpellier Cedex 7, France
| | - V Grobost
- Internal Medicine Department, CHU Estaing, 63100, Clermont-Ferrand, France
| | - M Rondeau-Lutz
- Internal Medicine Department, University Hospital of Strasbourg, 67091, Strasbourg Cedex, France
| | - O Dupuis
- Hôpital Lyon SUD, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, 69100, Villeurbanne, France
- Faculty of Medicine, Lyon University, 69921, Lyon, France
| | - N Ricard
- Biosanté unit U1292, Grenoble Alpes University, INSERM, CEA, 38000, Grenoble, France
| | - E Tillet
- Biosanté unit U1292, Grenoble Alpes University, INSERM, CEA, 38000, Grenoble, France
| | - P Machillot
- Biosanté unit U1292, Grenoble Alpes University, INSERM, CEA, 38000, Grenoble, France
| | - A Salomon
- Biosanté unit U1292, Grenoble Alpes University, INSERM, CEA, 38000, Grenoble, France
| | - C Picart
- Biosanté unit U1292, Grenoble Alpes University, INSERM, CEA, 38000, Grenoble, France
| | - C Battail
- Biosanté unit U1292, Grenoble Alpes University, INSERM, CEA, 38000, Grenoble, France
| | - S Dupuis-Girod
- Biosanté unit U1292, Grenoble Alpes University, INSERM, CEA, 38000, Grenoble, France
- Genetics Department, Femme-Mère-Enfants Hospital, Hospices Civils de Lyon, 69677, Bron, France
- National Reference Center for HHT, 69677, Bron, France
| | - C Guignabert
- Faculté de Médecine, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Université Paris-Saclay, 94276, Le Kremlin-Bicêtre, France
- INSERM UMR_S 999 «Pulmonary Hypertension: Pathophysiology and Novel Therapies», Hôpital Marie Lannelongue, 92350, Le Plessis-Robinson, France
| | - A Desroches-Castan
- Biosanté unit U1292, Grenoble Alpes University, INSERM, CEA, 38000, Grenoble, France
| | - S Bailly
- Biosanté unit U1292, Grenoble Alpes University, INSERM, CEA, 38000, Grenoble, France.
| |
Collapse
|
2
|
Desroches-Castan A, Koca D, Liu H, Roelants C, Resmini L, Ricard N, Bouvard C, Chaumontel N, Tharaux PL, Tillet E, Battail C, Lenoir O, Bailly S. BMP9 is a key player in endothelial identity and its loss is sufficient to induce arteriovenous malformations. Cardiovasc Res 2024:cvae052. [PMID: 38502919 DOI: 10.1093/cvr/cvae052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Revised: 10/10/2023] [Accepted: 12/18/2023] [Indexed: 03/21/2024] Open
Abstract
AIMS BMP9 is a high affinity ligand of ALK1 and endoglin receptors that are mutated in the rare genetic vascular disorder Hereditary Hemorrhagic Telangiectasia (HHT). We have previously shown that loss of Bmp9 in the 129/Ola genetic background leads to spontaneous liver fibrosis via capillarization of liver sinusoidal endothelial cells (LSEC) and kidney lesions. We aimed to decipher the molecular mechanisms downstream of BMP9 to better characterize its role in vascular homeostasis in different organs. METHODS AND RESULTS For this, we performed a RNAseq analysis on LSEC from adult WT and Bmp9-KO mice and identified over 2000 differentially expressed genes. Gene ontology analysis showed that Bmp9 deletion led to a decrease in BMP and Notch signaling, but also LSEC capillary identity while increasing their cell cycle. The gene ontology term "glomerulus development" was also negatively enriched in Bmp9-KO mice versus WT supporting a role for BMP9 in kidney vascularization. Through different imaging approaches (electron microscopy, immunostainings), we found that loss of Bmp9 led to vascular enlargement of the glomeruli capillaries associated with alteration of podocytes. Importantly, we also showed for the first time that the loss of Bmp9 led to spontaneous arteriovenous malformations (AVMs) in the liver, gastro-intestinal tract and uterus. CONCLUSIONS Altogether, these results demonstrate that BMP9 plays an important role in vascular quiescence both locally in the liver by regulating endothelial capillary differentiation markers and cell cycle but also at distance in many organs via its presence in the circulation. It also reveals that loss of Bmp9 is sufficient to induce spontaneous AVMs, supporting a key role for BMP9 in the pathogenesis of HHT.
Collapse
Affiliation(s)
- A Desroches-Castan
- Laboratoire Biosanté U1292, Université Grenoble Alpes, Inserm, CEA, Grenoble, France
| | - D Koca
- Laboratoire Biosanté U1292, Université Grenoble Alpes, Inserm, CEA, Grenoble, France
| | - H Liu
- Laboratoire Biosanté U1292, Université Grenoble Alpes, Inserm, CEA, Grenoble, France
| | - C Roelants
- Laboratoire Biosanté U1292, Université Grenoble Alpes, Inserm, CEA, Grenoble, France
| | - L Resmini
- Université Paris Cité, Inserm, PARCC, Paris, France
| | - N Ricard
- Laboratoire Biosanté U1292, Université Grenoble Alpes, Inserm, CEA, Grenoble, France
| | - C Bouvard
- Laboratoire Biosanté U1292, Université Grenoble Alpes, Inserm, CEA, Grenoble, France
| | - N Chaumontel
- Laboratoire Biosanté U1292, Université Grenoble Alpes, Inserm, CEA, Grenoble, France
| | - P L Tharaux
- Université Paris Cité, Inserm, PARCC, Paris, France
| | - E Tillet
- Laboratoire Biosanté U1292, Université Grenoble Alpes, Inserm, CEA, Grenoble, France
| | - C Battail
- Laboratoire Biosanté U1292, Université Grenoble Alpes, Inserm, CEA, Grenoble, France
| | - O Lenoir
- Université Paris Cité, Inserm, PARCC, Paris, France
| | - S Bailly
- Laboratoire Biosanté U1292, Université Grenoble Alpes, Inserm, CEA, Grenoble, France
| |
Collapse
|
3
|
Chaouki A, Roelants V, Gheysens O, Bailly S, Krug B. Extramedullary Hematopoiesis in Treated Diffuse Large B-Cell Lymphoma of Bone. Clin Nucl Med 2023; 48:1066-1067. [PMID: 37882755 DOI: 10.1097/rlu.0000000000004885] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2023]
Abstract
ABSTRACT A 65-year-old man with a history of diffuse large B-cell bone lymphoma of the right radius underwent an interim FDG PET/CT after 2 cycles of chemotherapy. Besides a complete metabolic response on the primary site, images revealed a hypermetabolic nodule in the posterior mediastinum, not present on the initial images. The metabolic activity of the nodule was similar to that of the reactive bone marrow and disappeared, concomitantly to the normalization of the medullar signal on the posttreatment images. The similarity and synchronous metabolic activity evolution in the nodule and bone marrow indicate extramedullary hematopoiesis.
Collapse
Affiliation(s)
- Amine Chaouki
- From the Department of Nuclear Medicine, CHU UCL Namur, Godinne Site, Université Catholique de Louvain
| | | | | | - Sarah Bailly
- Adult Hematology, Cliniques Universitaires Saint-Luc, Brussels, Université Catholique de Louvain, Leuven, Belgium
| | - Bruno Krug
- From the Department of Nuclear Medicine, CHU UCL Namur, Godinne Site, Université Catholique de Louvain
| |
Collapse
|
4
|
Lefebvre M, Gross L, Ollivier R, Bailly S, Coste-Burel M, Coutherut J, Dina J. Measles in vulnerable populations: An outbreak in Roma settlements of Loire-Atlantique, France, 2019. J Med Virol 2023; 95:e29321. [PMID: 38108193 DOI: 10.1002/jmv.29321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2023] [Revised: 11/07/2023] [Accepted: 12/04/2023] [Indexed: 12/19/2023]
Abstract
In May 2019, a measles outbreak occurred in the French subregion of Loire-Atlantique, particularly affecting Roma settlements. Various obstacles hindered the implementation of postexposure measures among Roma population, resulting in the spread of the cases to other settlements. Suspected cases of measles were immediately investigated and concerned settlements were visited for measles-mumps-rubella (MMR) vaccination. From July 1 to September 3, 2019, a first and then a second Health Reserve team helped for vaccination on the affected and then also the measles-free settlements. Vaccination uptake was monitored with the use of the department's vaccination center immunization registry. Genotyping of selected samples was performed for comparison with viruses circulating at the same time in France and Romania. As of September 16 2019, 109 cases of measles were confirmed among Roma population, including 99 (91%) children under 15 years. Of the 85 people eligible for vaccination, 60 (71%) had not been vaccinated and 23 (27%) had an unknown vaccination status. Sequence comparison revealed that 28/29 sequenced D8 strains were 100% identical to the strain responsible for a large number of cases throughout France in 2019, and to two sequences reported in Romania among sporadic cases. The vaccination campaign resulted in 1136 people on 35 settlements receiving at least one dose of MMR vaccine and in the increase of one-dose MMR vaccine coverage at 24 months from 43% (23/53) to 91% (48/53). With measles transmission continuing in Europe, efforts must be made to meet immunization coverage targets, particularly in hard-to-reach communities where outbreaks may be difficult to control.
Collapse
Affiliation(s)
- M Lefebvre
- Infectious Disease Department, Nantes University Hospital and Inserm CIC 1413, Nantes University, Nantes, France
- Center for Prevention of Infectious and Transmissible Diseases, Nantes University Hospital, Nantes, France
| | - L Gross
- Regional Health Agency in Pays de la Loire, Nantes, France
| | - R Ollivier
- Santé publique France, Regional Office in Pays de la Loire, Nantes, France
| | - S Bailly
- Center for Prevention of Infectious and Transmissible Diseases, Nantes University Hospital, Nantes, France
| | - M Coste-Burel
- Virology Department, Nantes University Hospital, Nantes, France
| | - J Coutherut
- Center for Prevention of Infectious and Transmissible Diseases, Nantes University Hospital, Nantes, France
| | - J Dina
- Department of Virology, Normandie Univ, UNICAEN, CHU de CAEN Normandie, Virology Department, INSERM UMR 1311, DYNAMICURE, Caen, France
- CHU de CAEN Normandie, National Reference Center for Measles, Mumps and Rubella viruses, Caen, France
| |
Collapse
|
5
|
Chomette L, Hupkens E, Romitti M, Dewachter L, Vachiéry JL, Bailly S, Costagliola S, Smits G, Tillet E, Bondue A. Pediatric pulmonary arterial hypertension due to a novel homozygous GDF2 missense variant affecting BMP9 processing and activity. Am J Med Genet A 2023. [PMID: 37249087 DOI: 10.1002/ajmg.a.63236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2023] [Revised: 03/14/2023] [Accepted: 04/27/2023] [Indexed: 05/31/2023]
Abstract
Pulmonary arterial hypertension (PAH) is a rare and severe disorder characterized by progressive pulmonary vasculopathy. Growth differentiation factor (GDF)2 encodes the pro-protein bone morphogenetic protein (BMP) 9, activated after cleavage by endoproteases into an active mature form. BMP9, together with BMP10, are high-affinity ligands of activin receptor-like kinase 1 (ALK1) and BMP receptor type II (BMPR2). GDF2 mutations have been reported in idiopathic PAH with most patients being heterozygous carriers although rare homozygous cases have been described. The link between PAH occurrence and BMP9 or 10 expression level is still unclear. In this study, we describe a pediatric case of PAH also presenting with telangiectasias and epistaxis. The patient carries the novel homozygous GDF2 c.946A > G mutation, replacing the first arginine of BMP9's cleavage site (R316) by a glycine. We show that this mutation leads to an absence of circulating mature BMP9 and mature BMP9-10 heterodimers in the patient's plasma although pro-BMP9 is still detected at a similar level as controls. In vitro functional studies further demonstrated that the mutation R316G hampers the correct processing of BMP9, leading to the secretion of inactive pro-BMP9. The heterozygous carriers of the variant were asymptomatic, similarly to previous reports, reinforcing the hypothesis of modifiers preventing/driving PAH development in heterozygous carriers.
Collapse
Affiliation(s)
- L Chomette
- Department of Cardiology, Hôpital Erasme, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles (ULB), Brussels, Belgium
- IRIBHM, Faculty of medicine, Université Libre de Bruxelles (ULB), Brussels, Belgium
| | - E Hupkens
- Laboratory of Physiology and Pharmacology (LAPP), Faculty of Medicine, Université Libre de Bruxelles (ULB), Brussels, Belgium
| | - M Romitti
- IRIBHM, Faculty of medicine, Université Libre de Bruxelles (ULB), Brussels, Belgium
| | - L Dewachter
- Laboratory of Physiology and Pharmacology (LAPP), Faculty of Medicine, Université Libre de Bruxelles (ULB), Brussels, Belgium
| | - J L Vachiéry
- Department of Cardiology, Hôpital Erasme, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles (ULB), Brussels, Belgium
| | - S Bailly
- Laboratory BioSanté, Université Grenoble Alpes, INSERM, CEA, Grenoble, France
| | - S Costagliola
- IRIBHM, Faculty of medicine, Université Libre de Bruxelles (ULB), Brussels, Belgium
| | - G Smits
- Department of Human Genetics, Hôpital Erasme, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles (ULB), Brussels, Belgium
| | - E Tillet
- Laboratory BioSanté, Université Grenoble Alpes, INSERM, CEA, Grenoble, France
| | - Antoine Bondue
- Department of Cardiology, Hôpital Erasme, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles (ULB), Brussels, Belgium
- IRIBHM, Faculty of medicine, Université Libre de Bruxelles (ULB), Brussels, Belgium
| |
Collapse
|
6
|
Robert F, Berrebeh N, Guignabert C, Humbert M, Bailly S, Tu L, Savale L. [Dysfunction of endothelial BMP-9 signaling in pulmonary vascular disease]. Rev Mal Respir 2023; 40:234-238. [PMID: 36828679 DOI: 10.1016/j.rmr.2023.01.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2023] [Accepted: 01/06/2023] [Indexed: 02/24/2023]
Abstract
The signaling pathway of the bone morphogenetic protein (BMP)-9 binding to the endothelial receptor BMP receptor type II (BMPR-II), activin receptor-like kinase-1 (ALK1) and the coreceptor endoglin is essential to maintain the pulmonary vascular integrity. Dysregulation of this pathway is implicated in numerous vascular diseases, such as pulmonary arterial hypertension (PAH), hereditary hemorrhagic telangiectasia (HHT) and hepatopulmonary syndrome (HPS). This article aims to provide a comprehensive review of the implication of the BMP-9/BMPR-II/ALK1/endoglin pathway in the pathophysiology of these diseases.
Collapse
Affiliation(s)
- F Robert
- Faculté de médecine, Université Paris-Saclay, Inserm UMR_S 999 - Bâtiment de recherche (2(e) étage), 63, rue Gabriel-Péri, 94276 Le Kremlin-Bicêtre, France; Inserm Unité mixte de recherche 999, Hôpital Marie-Lannelongue, 92350 Le Plessis-Robinson, France
| | - N Berrebeh
- Faculté de médecine, Université Paris-Saclay, Inserm UMR_S 999 - Bâtiment de recherche (2(e) étage), 63, rue Gabriel-Péri, 94276 Le Kremlin-Bicêtre, France; Inserm Unité mixte de recherche 999, Hôpital Marie-Lannelongue, 92350 Le Plessis-Robinson, France
| | - C Guignabert
- Faculté de médecine, Université Paris-Saclay, Inserm UMR_S 999 - Bâtiment de recherche (2(e) étage), 63, rue Gabriel-Péri, 94276 Le Kremlin-Bicêtre, France; Inserm Unité mixte de recherche 999, Hôpital Marie-Lannelongue, 92350 Le Plessis-Robinson, France
| | - M Humbert
- Faculté de médecine, Université Paris-Saclay, Inserm UMR_S 999 - Bâtiment de recherche (2(e) étage), 63, rue Gabriel-Péri, 94276 Le Kremlin-Bicêtre, France; Inserm Unité mixte de recherche 999, Hôpital Marie-Lannelongue, 92350 Le Plessis-Robinson, France; Service de pneumologie et soins intensifs respiratoires, Centre de référence de l'hypertension pulmonaire, Hôpital Bicêtre, Assistance publique-Hôpitaux de Paris (AP-HP), 94276 Le Kremlin-Bicêtre, France
| | - S Bailly
- Laboratoire BioSanté, Université Grenoble Alpes, INSERM, CEA, Grenoble, France
| | - L Tu
- Faculté de médecine, Université Paris-Saclay, Inserm UMR_S 999 - Bâtiment de recherche (2(e) étage), 63, rue Gabriel-Péri, 94276 Le Kremlin-Bicêtre, France; Inserm Unité mixte de recherche 999, Hôpital Marie-Lannelongue, 92350 Le Plessis-Robinson, France
| | - L Savale
- Faculté de médecine, Université Paris-Saclay, Inserm UMR_S 999 - Bâtiment de recherche (2(e) étage), 63, rue Gabriel-Péri, 94276 Le Kremlin-Bicêtre, France; Inserm Unité mixte de recherche 999, Hôpital Marie-Lannelongue, 92350 Le Plessis-Robinson, France; Service de pneumologie et soins intensifs respiratoires, Centre de référence de l'hypertension pulmonaire, Hôpital Bicêtre, Assistance publique-Hôpitaux de Paris (AP-HP), 94276 Le Kremlin-Bicêtre, France.
| |
Collapse
|
7
|
Hozé N, Salje H, Rousset D, Fritzell C, Vanhomwegen J, Bailly S, Najm M, Enfissi A, Manuguerra JC, Flamand C, Cauchemez S. Author Correction: Reconstructing Mayaro virus circulation in French Guiana shows frequent spillovers. Nat Commun 2023; 14:1064. [PMID: 36828849 PMCID: PMC9957981 DOI: 10.1038/s41467-023-36843-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/26/2023] Open
Affiliation(s)
- Nathanaël Hozé
- grid.428999.70000 0001 2353 6535Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, UMR2000, CNRS, 75015 Paris, France
| | - Henrik Salje
- grid.428999.70000 0001 2353 6535Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, UMR2000, CNRS, 75015 Paris, France ,grid.5335.00000000121885934Department of Genetics, University of Cambridge, Cambridge, UK
| | - Dominique Rousset
- Arbovirus National Reference Center, Institut Pasteur in French Guiana, Cayenne, French Guiana
| | - Camille Fritzell
- Epidemiology Unit, Institut Pasteur in French Guiana, Cayenne, French Guiana
| | - Jessica Vanhomwegen
- grid.428999.70000 0001 2353 6535Environment and Infectious Risks Unit, Institut Pasteur, Paris, France
| | - Sarah Bailly
- Epidemiology Unit, Institut Pasteur in French Guiana, Cayenne, French Guiana
| | - Matthieu Najm
- grid.428999.70000 0001 2353 6535Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, UMR2000, CNRS, 75015 Paris, France
| | - Antoine Enfissi
- Arbovirus National Reference Center, Institut Pasteur in French Guiana, Cayenne, French Guiana
| | - Jean-Claude Manuguerra
- grid.428999.70000 0001 2353 6535Environment and Infectious Risks Unit, Institut Pasteur, Paris, France
| | - Claude Flamand
- Epidemiology Unit, Institut Pasteur in French Guiana, Cayenne, French Guiana
| | - Simon Cauchemez
- Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, UMR2000, CNRS, 75015, Paris, France.
| |
Collapse
|
8
|
Berrebeh N, Thuillet R, Ottaviani M, Chelgham M, Anegon I, Schermuly R, Kojonazarov B, Humbert M, Bailly S, Guignabert C, Tu L. BMP-9 loss alters lung vascular integrity and partially attenuates experimental pulmonary hypertension. Rev Mal Respir 2023. [DOI: 10.1016/j.rmr.2022.11.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
|
9
|
Ramchandren R, Johnson P, Ghosh N, Ruan J, Ardeshna KM, Johnson R, Verhoef G, Cunningham D, de Vos S, Kassam S, Fayad L, Radford J, Bailly S, Offner F, Morgan D, Munoz J, Ping J, Szafer-Glusman E, Eckert K, Neuenburg JK, Goy A. The iR 2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study. EClinicalMedicine 2023; 56:101779. [PMID: 36618900 PMCID: PMC9813677 DOI: 10.1016/j.eclinm.2022.101779] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/09/2022] [Revised: 11/17/2022] [Accepted: 11/22/2022] [Indexed: 12/27/2022] Open
Abstract
BACKGROUND This phase 1b/2 PCYC-1123-CA study evaluated efficacy and safety of the combination of ibrutinib, lenalidomide, and rituximab (iR2 regimen) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) ineligible for stem cell transplantation. METHODS In phase 2, patients with relapsed/refractory non-germinal centre B-cell-like DLBCL received oral ibrutinib 560 mg once daily and oral lenalidomide 20 mg or 25 mg once daily on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity and intravenous rituximab 375 mg/m2 on Day 1 of Cycles 1-6. The primary endpoint was overall response rate (ORR) in the response-evaluable population (received any study treatment and had ≥1 post-baseline disease assessment). The study was done at 24 academic and community hospitals in Belgium, Germany, United Kingdom, and USA. This study was registered with ClinicalTrials.gov, NCT02077166. FINDINGS Between March 13, 2014 and October 2, 2018, 89 patients were enrolled with a median time on study of 35.0 months. Best ORR in the response-evaluable population (n = 85) was 49% (95% confidence interval [CI], 38-61) across dose cohorts and 53% (95% CI, 39-67) and 44% (95% CI, 26-62) in the 20 mg and 25 mg lenalidomide cohorts, respectively, with complete responses in 24/85 (28%), 17/53 (32%), and 7/32 (22%) patients, respectively. Grade 3/4 adverse events (AEs) occurred in 81/89 patients (91%), most frequently neutropenia (36/89; 40%), maculopapular rash (16/89; 18%), anaemia (12/89; 13%), and diarrhoea (9/89; 10%). Serious adverse events occurred in 57/89 patients (64%). Fatal AEs occurred in 12/89 patients (13%); causes of death were worsening of DLBCL (n = 7), pneumonia (n = 3), sepsis (n = 1), and cardiac arrest (n = 1). INTERPRETATION The most frequent AEs (diarrhoea, neutropenia, fatigue, cough, anaemia, peripheral oedema, and maculopapular rash) were consistent with known safety profiles of the individual drugs. The iR2 regimen demonstrated antitumour activity with durable responses in patients with relapsed/refractory DLBCL. FUNDING Pharmacyclics LLC, an AbbVie Company.
Collapse
Affiliation(s)
- Radhakrishnan Ramchandren
- Division of Hematology/Oncology, University of Tennessee Health Science Center, Knoxville, TN, USA
- Corresponding author. University of Tennessee Health Science Center, 1926 Alcoa Highway, Building F, Suite 410, Knoxville, TN 37920, USA.
| | - Peter Johnson
- Cancer Research UK Clinical Centre, Southampton General Hospital, Southampton, UK
| | - Nilanjan Ghosh
- Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
| | - Jia Ruan
- Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA
| | - Kirit M. Ardeshna
- University College London/UCL Hospitals, Biomedical Research Centre, London, UK
| | - Roderick Johnson
- Leeds Cancer Centre at St. James's University Hospital, Leeds, UK
| | - Gregor Verhoef
- Department of Haematology, UZ Leuven – Campus Gasthuisberg, Leuven, Belgium
| | - David Cunningham
- Gastrointestinal and Lymphoma Unit, The Royal Marsden NHS Foundation Trust – Royal Marsden Hospital, London, UK
| | - Sven de Vos
- Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
| | - Shireen Kassam
- Haematology Department, King's College Hospital, London, UK
| | - Luis Fayad
- Department of Lymphoma-Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - John Radford
- Division of Cancer Sciences, The University of Manchester and the Christie NHS Foundation Trust, Manchester, UK
| | - Sarah Bailly
- Cliniques Universitaires Saint-Luc, Université Catholique de Louvain Brussels, Brussels, Belgium
| | - Fritz Offner
- Department of Clinical Hematology, Universitair Ziekenhuis Gent, Ghent, Belgium
| | - David Morgan
- Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
| | - Javier Munoz
- Department of Hematology, Banner MD Anderson Cancer Center, Gilbert, AZ, USA
| | - Jerry Ping
- Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USA
| | | | - Karl Eckert
- Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USA
| | | | - Andre Goy
- Department of Hematology & Oncology, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA
| |
Collapse
|
10
|
Pépin JL, Bailly S, Jean-Deleglise AS, Girfoglio D, Gagnadoux F. Post reimbursement analysis of the impact of solriamfetol prescription on CPAP adherence (SOPRANO): Design of a nationwide retrospective analysis in real-world CPAP-treated French patients with OSA. Sleep Med 2022. [DOI: 10.1016/j.sleep.2022.05.722] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
11
|
Yildiz H, Castanares-Zapatero D, d’Abadie P, Bailly S, Yombi JC. Hemophagocytic Lymphohistiocytosis in Adults: A Retrospective Study in a Belgian Teaching Hospital. Int J Gen Med 2022; 15:8111-8120. [PMID: 36389021 PMCID: PMC9653050 DOI: 10.2147/ijgm.s388880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2022] [Accepted: 11/03/2022] [Indexed: 11/09/2022] Open
Abstract
Introduction Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disease, which can be primary (due to genetic mutation) or secondary to malignancy, infection and rheumatologic diseases. Data concerning Belgian patients with adult HLH are lacking. Methods This retrospective study was performed in a teaching hospital in Belgium. All cases of adult HLH, from December 2010 to April 2022, were reviewed. Patients with more than five HLH-2004 criteria and/or HScore >80% were included in the study. The objective of our study was to describe clinical and biological characteristics of patients with HLH and attempt to look for variables associated with mortality. Results Fifty-two patients were included in the final analysis. Mean age (SD) of patients was 48 (18) years old, and 29 patients were of male gender (56%). The underlying diseases associated with HLH were malignancy (M-HLH) in 22 patients, infection related HLH in 20 patients, rheumatologic disease related HLH in 7 patients, idiopathic in 2 patients and secondary to pregnancy in 1 patient. Overall mortality, mortality at 30 days and 90 days were 24/52 (46%), 13/52 (25%) and 4/52 (10%), respectively. In univariate analysis, malignancy, male sex, age and disseminated intravascular coagulation (DIC) were associated with mortality (p < 0.05). In multivariate analysis, only age was significantly associated with mortality (odds ratio, 1.053; 95% confidence interval, 1.016–1.092; p 0.005). Conclusion In our study, the most frequent triggers were malignancy and infectious agent followed by rheumatologic disease. Risk factors for mortality were age, male sex, malignancy and DIC, but only age remained significant in multivariate analysis. Treatment guidelines are mainly based on pediatric patients, and it is important for physician to describe adult patients’ outcome to better understand this disease and adapt treatment.
Collapse
Affiliation(s)
- Halil Yildiz
- Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, UClouvain, Bruxelles, Belgium
- Correspondence: Halil Yildiz, Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, UClouvain, 10 Av Hippocrate, Bruxelles, 1200, Belgium, Email
| | | | - Philippe d’Abadie
- Department of Nuclear Medicine, Cliniques Universitaires Saint-Luc, UClouvain, Bruxelles, Belgium
| | - Sarah Bailly
- Department of Hematology, Cliniques Universitaires Saint-Luc, UClouvain, Bruxelles, Belgium
| | - Jean Cyr Yombi
- Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, UClouvain, Bruxelles, Belgium
| |
Collapse
|
12
|
Bailly S, Hozé N, Bisser S, Zhu-Soubise A, Fritzell C, Fernandes-Pellerin S, Mbouangoro A, Rousset D, Djossou F, Cauchemez S, Flamand C. Transmission dynamics of Q fever in French Guiana: A population-based cross-sectional study. Lancet Reg Health Am 2022; 16:100385. [PMID: 36777152 PMCID: PMC9903881 DOI: 10.1016/j.lana.2022.100385] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/12/2022] [Revised: 08/20/2022] [Accepted: 10/10/2022] [Indexed: 11/06/2022]
Abstract
Background Q fever is a zoonosis caused by Coxiella burnetii which is among the major agents of community-acquired pneumonia in French Guiana. Despite its relatively high incidence, its epidemiology in French Guiana remains unclear, and all previous studies have considered transmission from livestock unlikely, suggesting that a wild reservoir is responsible for transmission. Methods A country-wide seroprevalence survey of 2697 participants from French Guiana was conducted. Serum samples were tested for phase II IgG antibodies by ELISA and indirect immunofluorescence assays (IFAs). Factors associated with Q fever were investigated, and a serocatalytic model was used to reconstruct the annual force of infection. Findings The overall weighted seroprevalence was estimated at 9.6% (95% confidence interval (CI): 8.2%-11.0%). The model revealed constant, low-level circulation across French Guiana, particularly affecting middle-aged males (odds ratio (OR): 3.0, 95% credible interval (CrI): 1.7-5.8) and individuals living close to sheep farms (OR: 4, 95% CrI: 1.5-12). The overall annual number of cases was estimated at 579 (95% CrI: 492-670). In the region around Cayenne, the main urban municipality, the high seroprevalence was explained by an outbreak that may have occurred between 1996 and 2003 and that infected 10% (95% CrI: 6.9%-14%) of the population and males and females alike. Interpretation This study reveals for the first time Q fever dynamics of transmission and the role of domestic livestock in transmission in French Guiana and highlights the urgent need to reinforce Q fever surveillance in livestocks of the entire Guianese territory. Funding This study was supported by the "European Regional Development Fund" under EPI-ARBO grant agreement (GY0008695), the "Regional Health Agency of French Guiana" and the "National Center of Spatial Studies". The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Collapse
Affiliation(s)
- Sarah Bailly
- Epidemiology Unit, Institut Pasteur in French Guiana, Cayenne, French Guiana
| | - Nathanaël Hozé
- Mathematical Modeling of Infectious Diseases Unit, Institut Pasteur, Université Paris Cité, UMR2000, CNRS, Paris, France
| | - Sylvie Bisser
- Medical Laboratory, Institut Pasteur in French Guiana, Cayenne, French Guiana
| | | | - Camille Fritzell
- Epidemiology Unit, Institut Pasteur in French Guiana, Cayenne, French Guiana
| | | | - Adija Mbouangoro
- Medical Laboratory, Institut Pasteur in French Guiana, Cayenne, French Guiana
| | - Dominique Rousset
- Virology Laboratory, Institut Pasteur in French Guiana, Cayenne, French Guiana
| | - Félix Djossou
- Infectious and Tropical Disease Unit, Centre Hospitalier de Cayenne, Cayenne, French Guiana
| | - Simon Cauchemez
- Mathematical Modeling of Infectious Diseases Unit, Institut Pasteur, Université Paris Cité, UMR2000, CNRS, Paris, France
| | - Claude Flamand
- Epidemiology Unit, Institut Pasteur in French Guiana, Cayenne, French Guiana,Mathematical Modeling of Infectious Diseases Unit, Institut Pasteur, Université Paris Cité, UMR2000, CNRS, Paris, France,Corresponding author.
| |
Collapse
|
13
|
Bailly S, Cartron G, Chaganti S, Córdoba R, Corradini P, Düll J, Ferrarini I, Osborne W, Rosenwald A, Sancho J, Tilly H, Van Den Neste E, Viardot A, Visco C. Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paper. Hematol Oncol 2022; 40:505-517. [PMID: 35488888 PMCID: PMC9796473 DOI: 10.1002/hon.3013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2022] [Accepted: 04/07/2022] [Indexed: 01/01/2023]
Abstract
The ubiquitous, early-stage expression, efficient internalization, limited off-target effects, and high disease specificity of CD19 make it an attractive therapeutic target. Currently available anti-CD19 therapies have demonstrated particular promise in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Selection of the most appropriate treatment strategy should be based on individual patient characteristics and the goal of therapy. However, evidence and knowledge about the sequencing of anti-CD19 therapies are limited. Here, we review the current evidence for CD19 as a target in diffuse large B-cell lymphoma and consider approaches to the use of anti-CD19 therapy.
Collapse
Affiliation(s)
- Sarah Bailly
- Département d’HématologieCliniques Universitaires Saint‐LucBrusselsBelgium
| | - Guillaume Cartron
- Department of HaematologyCentre Hospitalier Universitaire de MontpellierUMR‐CNRS 5535MontpellierFrance
| | | | - Raul Córdoba
- Department of HematologyFundación Jiménez Díaz University HospitalHealth Research Institute IIS‐FJDMadridSpain
| | - Paolo Corradini
- Fondazione IRCCS Istituto Nazionale dei TumoriUniversity of MilanMilanItaly
| | - Johannes Düll
- Medizinische Klinik und Poliklinik IIUniversitätsklinikum WürzburgWürzburgGermany
| | - Isacco Ferrarini
- Department of MedicineSection of HematologyUniversity of VeronaVeronaItaly
| | - Wendy Osborne
- Newcastle Upon Tyne Hospitals NHS Foundation TrustNewcastleUK
| | - Andreas Rosenwald
- Institute of PathologyUniversity of Würzburg, and Comprehensive Cancer Center MainfrankenWürzburgGermany
| | | | - Hervé Tilly
- Department of Hematology and U1245Centre Henri Becquerel and University of RouenRouenFrance
| | - Eric Van Den Neste
- Département d’HématologieCliniques Universitaires Saint‐LucBrusselsBelgium
| | - Andreas Viardot
- Department of Internal Medicine IIIUniversity Hospital UlmUlmGermany
| | - Carlo Visco
- Department of MedicineSection of HematologyUniversity of VeronaVeronaItaly
| |
Collapse
|
14
|
Hoornaert E, Dachy F, Hansenne A, Bailly S, van Maanen A, Gruson D, Vekemans MC. COVID-19: impact of vaccination in myeloma patients. Ann Hematol 2022; 101:1607-1608. [PMID: 35411439 PMCID: PMC9001015 DOI: 10.1007/s00277-022-04799-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2022] [Accepted: 02/14/2022] [Indexed: 11/29/2022]
Affiliation(s)
- E Hoornaert
- Department of Internal Medicine and Infectious Diseases, Cliniques universitaires Saint Luc, 10 avenue Hippocrate, 1200 Woluwe Saint Lambert, Brussels, Belgium.
| | - F Dachy
- Department of Hematology, Cliniques universitaires Saint Luc, 1200, Brussels, Belgium
| | - A Hansenne
- Department of Hematology, Cliniques universitaires Saint Luc, 1200, Brussels, Belgium
| | - S Bailly
- Department of Hematology, Cliniques universitaires Saint Luc, 1200, Brussels, Belgium
| | - A van Maanen
- Statistical Support Unit, King Albert II Institute, Cliniques Universitaires Saint Luc, 1200, Brussels, Belgium
| | - D Gruson
- Department of Laboratory Medicine, Cliniques universitaires Saint Luc, 1200, Brussels, Belgium
| | - M-C Vekemans
- Department of Hematology, Cliniques universitaires Saint Luc, 1200, Brussels, Belgium
| |
Collapse
|
15
|
Flamand C, Alves Sarmento C, Enfissi A, Bailly S, Beillard E, Gaillet M, Michaud C, Servas V, Clement N, Perilhou A, Carage T, Musso D, Carod JF, Eustache S, Tourbillon C, Boizon E, James S, Djossou F, Salje H, Cauchemez S, Rousset D. Seroprevalence of anti-SARS-CoV-2 IgG at the first epidemic peak in French Guiana, July 2020. PLoS Negl Trop Dis 2021; 15:e0009945. [PMID: 34767549 PMCID: PMC8639096 DOI: 10.1371/journal.pntd.0009945] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2020] [Revised: 12/02/2021] [Accepted: 10/22/2021] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND While Latin America has been heavily affected by the pandemic, only a few seroprevalence studies have been conducted there during the first epidemic wave in the first half of 2020. METHODOLOGY/PRINCIPAL FINDINGS A cross-sectional survey was performed between 15 July 2020 and 23 July 2020 among individuals who visited 4 medical laboratories or 5 health centers for routine screening or clinical management, with the exception of symptomatic suggestive cases of covid-19. Samples were screened for the presence of anti-SARS-CoV-2 IgG directed against domain S1 of the SARS-CoV-2 spike protein using the anti-SARS-CoV-2 enzyme-linked immunosorbent assay (ELISA) from Euroimmun. CONCLUSIONS/SIGNIFICANCE The overall seroprevalence was 15.4% [9.3%-24.4%] among 480 participants, ranging from 4.0% to 25.5% across the different municipalities. The seroprevalence did not differ according to gender (p = 0.19) or age (p = 0.51). Among SARS-CoV-2 positive individuals, we found that 24.6% [11.5%-45.2%] reported symptoms consistent with COVID-19. Our findings revealed high levels of infection across the territory but a low number of resulting deaths, which can be explained by French Guiana's young population structure.
Collapse
Affiliation(s)
- Claude Flamand
- Epidemiology unit, Institut Pasteur in French Guiana, Cayenne, French Guiana
- Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, UMR2000, CNRS, Paris, France
| | | | - Antoine Enfissi
- Laboratory of Virology, Institut Pasteur in French Guiana, Cayenne, French Guiana
| | - Sarah Bailly
- Epidemiology unit, Institut Pasteur in French Guiana, Cayenne, French Guiana
| | - Emmanuel Beillard
- Medical Biology Laboratory, Institut Pasteur in French Guiana, Cayenne, French Guiana
| | - Mélanie Gaillet
- Health Centers Department, Cayenne Hospital Center, Cayenne, French Guiana
| | - Céline Michaud
- Health Centers Department, Cayenne Hospital Center, Cayenne, French Guiana
| | - Véronique Servas
- Health Centers Department, Cayenne Hospital Center, Cayenne, French Guiana
| | - Nathalie Clement
- Clinical Core of the Center for Translational Sciences, Institut Pasteur, Paris, France
| | - Anaïs Perilhou
- Clinical Core of the Center for Translational Sciences, Institut Pasteur, Paris, France
| | - Thierry Carage
- Carage Medical Biology Laboratory, Kourou, French Guiana
| | - Didier Musso
- Laboratoires Eurofins Labazur Guyane, Remire, French Guiana
- Aix Marseille University, IRD, AP-HM, SSA, VITROME, IHU-Méditerranée Infection, Marseille, France
| | - Jean-françois Carod
- Medical Biology laboratory, Centre Hospitalier de l’Ouest Guyanais, Saint-Laurent du Maroni, French Guiana
| | - Stéphanie Eustache
- Epidemiology unit, Institut Pasteur in French Guiana, Cayenne, French Guiana
| | - Céline Tourbillon
- Epidemiology unit, Institut Pasteur in French Guiana, Cayenne, French Guiana
| | - Elodie Boizon
- Epidemiology unit, Institut Pasteur in French Guiana, Cayenne, French Guiana
| | - Samantha James
- Epidemiology unit, Institut Pasteur in French Guiana, Cayenne, French Guiana
| | - Félix Djossou
- Infectious and Tropical Diseases Unit, Cayenne Hospital Center, Cayenne, French Guiana
| | - Henrik Salje
- Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, UMR2000, CNRS, Paris, France
- Department of Genetics, University of Cambridge, Cambridge, United Kingdom
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America
| | - Simon Cauchemez
- Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, UMR2000, CNRS, Paris, France
| | - Dominique Rousset
- Laboratory of Virology, Institut Pasteur in French Guiana, Cayenne, French Guiana
| |
Collapse
|
16
|
Saad Albichr I, De Greef J, Van Den Neste E, Poiré X, Havelange V, Vekemans MC, Bailly S, Yombi JC, Mzougui S, Scohy A, Kabamba-Mukadi B. Cellular response to COVID-19 vaccines in hematologic malignancies patients: a new hope for non-responders? Leuk Lymphoma 2021; 63:743-746. [PMID: 34706604 PMCID: PMC8567276 DOI: 10.1080/10428194.2021.1998485] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- Imane Saad Albichr
- Department of Microbiology, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium
| | - Julien De Greef
- Department of Internal Medicine and Infectious Disease, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium
| | - Eric Van Den Neste
- Department of Hematology, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium
| | - Xavier Poiré
- Department of Hematology, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium
| | - Violaine Havelange
- Department of Hematology, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium
| | | | - Sarah Bailly
- Department of Hematology, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium
| | - Jean-Cyr Yombi
- Department of Internal Medicine and Infectious Disease, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium
| | - Samy Mzougui
- Department of Microbiology, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium
| | - Anaïs Scohy
- Department of Microbiology, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium
| | - Benoît Kabamba-Mukadi
- Department of Microbiology, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium
| |
Collapse
|
17
|
Levy G, Mambet C, Pecquet C, Bailly S, Havelange V, Diaconu CC, Constantinescu SN. Targets in MPNs and potential therapeutics. Int Rev Cell Mol Biol 2021; 366:41-81. [PMID: 35153006 DOI: 10.1016/bs.ircmb.2021.06.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Philadelphia-negative classical Myeloproliferative Neoplasms (MPNs), including Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF), are clonal hemopathies that emerge in the hematopoietic stem cell (HSC) compartment. MPN driver mutations are restricted to specific exons (14 and 12) of Janus kinase 2 (JAK2), thrombopoietin receptor (MPL/TPOR) and calreticulin (CALR) genes, are involved directly in clonal myeloproliferation and generate the MPN phenotype. As a result, an increased number of fully functional erythrocytes, platelets and leukocytes is observed in the peripheral blood. Nevertheless, the complexity and heterogeneity of MPN clinical phenotypes cannot be solely explained by the type of driver mutation. Other factors, such as additional somatic mutations affecting epigenetic regulators or spliceosomes components, mutant allele burdens and modifiers of signaling by driver mutants, clonal architecture and the order of mutation acquisition, signaling events that occur downstream of a driver mutation, the presence of specific germ-line variants, the interaction of the neoplastic clone with bone marrow microenvironment and chronic inflammation, all can modulate the disease phenotype, influence the MPN clinical course and therefore, might be useful therapeutic targets.
Collapse
Affiliation(s)
- Gabriel Levy
- Ludwig Institute for Cancer Research, Brussels, Belgium; SIGN Unit, de Duve Institute, Université Catholique de Louvain, Brussels, Belgium; Department of Pediatric Hematology and Oncology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
| | - Cristina Mambet
- Department of Cellular and Molecular Pathology, Stefan S. Nicolau Institute of Virology, Bucharest, Romania; Department of Hematology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
| | - Christian Pecquet
- Ludwig Institute for Cancer Research, Brussels, Belgium; SIGN Unit, de Duve Institute, Université Catholique de Louvain, Brussels, Belgium; WELBIO (Walloon Excellence in Life Sciences and Biotechnology), Brussels, Belgium
| | - Sarah Bailly
- Ludwig Institute for Cancer Research, Brussels, Belgium; SIGN Unit, de Duve Institute, Université Catholique de Louvain, Brussels, Belgium; Department of Hematology, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels, Belgium
| | - Violaine Havelange
- SIGN Unit, de Duve Institute, Université Catholique de Louvain, Brussels, Belgium; Department of Hematology, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels, Belgium
| | - Carmen C Diaconu
- Department of Cellular and Molecular Pathology, Stefan S. Nicolau Institute of Virology, Bucharest, Romania
| | - Stefan N Constantinescu
- Ludwig Institute for Cancer Research, Brussels, Belgium; SIGN Unit, de Duve Institute, Université Catholique de Louvain, Brussels, Belgium; WELBIO (Walloon Excellence in Life Sciences and Biotechnology), Brussels, Belgium; Ludwig Institute for Cancer Research, Nuffield Department of Medicine, Oxford University, Oxford, United Kingdom.
| |
Collapse
|
18
|
Hansenne A, Camboni A, Van Den Neste E, Bailly S. Richter transformation heralded by EBV reactivation during ibrutinib therapy for chronic lymphocytic leukemia. Leuk Lymphoma 2021; 62:3051-3053. [PMID: 34429010 DOI: 10.1080/10428194.2021.1964023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- Amandine Hansenne
- Service d'hématologie, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), Brussels, Belgium
| | - Alessandra Camboni
- Service d'anatomie Pathologique, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), Brussels, Belgium
| | - Eric Van Den Neste
- Service d'hématologie, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), Brussels, Belgium
| | - Sarah Bailly
- Service d'hématologie, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), Brussels, Belgium
| |
Collapse
|
19
|
Camus V, Rossi C, Sesques P, Lequesne J, Tonnelet D, Haioun C, Durot E, Willaume A, Gauthier M, Moles‐Moreau M, Antier C, Lazarovici J, Monjanel H, Bernard S, Tardy M, Besson C, Lebras L, Choquet S, Le Du K, Bonnet C, Bailly S, Damaj G, Laribi K, Maisonneuve H, Houot R, Chauchet A, Jardin F, Traverse‐Glehen A, Decazes P, Becker S, Berriolo‐Riedinger A, Tilly H. OUTCOMES AFTER FIRST‐LINE IMMUNOCHEMOTHERAPY FOR PRIMARY MEDIASTINAL B CELL LYMPHOMA PATIENTS: A LYSA STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.50_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- V. Camus
- Centre Henri Becquerel Department of Hematology Rouen France
| | - C. Rossi
- Dijon University Hospital Hematology Dijon France
| | - P. Sesques
- CHU Lyon Sud, Hematology Pierre‐Bénite France
| | - J. Lequesne
- Centre Henri Becquerel Clinical Research Unit Rouen France
| | - D. Tonnelet
- Centre Henri Becquerel Department of Nuclear Medicine Rouen France
| | - C. Haioun
- CHU Mondor, Hematology Créteil France
| | - E. Durot
- CHU Reims Hematology Reims France
| | | | | | | | | | | | | | | | - M. Tardy
- Centre Antoine Lacassagne Hematology Nice France
| | - C. Besson
- Centre Hospitalier de Versailles Hematology Le Chesnay France
| | - L. Lebras
- Centre Leon Berard Hematology Lyon France
| | - S. Choquet
- CHU La pitié salpetriere Hematology Paris France
| | - K. Le Du
- Clinique Victor Hugo Hematology Le Mans France
| | - C. Bonnet
- Liege University Hospital Hematology Liege Belgium
| | - S. Bailly
- Cliniques Universitaires Saint Luc Hematology Bruxelles Belgium
| | | | - K. Laribi
- CH Le Mans Hematology Le Mans France
| | - H. Maisonneuve
- CH Departemental de Vendée Hematology la Roche sur Yon France
| | - R. Houot
- CHU Rennes Hematology Rennes France
| | | | - F. Jardin
- Centre Henri Becquerel Department of Hematology Rouen France
| | | | - P. Decazes
- Centre Henri Becquerel Department of Nuclear Medicine Rouen France
| | - S. Becker
- Centre Henri Becquerel Department of Nuclear Medicine Rouen France
| | | | - H. Tilly
- Centre Henri Becquerel Department of Hematology Rouen France
| |
Collapse
|
20
|
Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E, Lancesseur C, Le Bras F, Willems E, Tchernonog E, Chalopin T, Delarue R, Gressin R, Chauchet A, Gyan E, Cartron G, Bonnet C, Haioun C, Damaj G, Gaulard P, Fornecker L, Ghesquières H, Tournilhac O, Gomesda Silva M, Bouabdallah R, Salles G, Bachy E. Corrigendum to 'Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers': [Annals of Oncology Volume 29, Issue 3, March 2018, Pages 715-723]. Ann Oncol 2021; 32:945. [PMID: 33992519 DOI: 10.1016/j.annonc.2021.04.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
Affiliation(s)
- G Fossard
- Hematology Department, CHU Lyon Sud, Hospices Civils de Lyon, Pierre Benite, France; Claude Bernard Lyon 1 University, Lyon, France; Cancer Center of Lyon (CRCL), INSERM U1052 - CNRS UMR5286, Lyon, France
| | - F Broussais
- Hematology Department, CHU Lyon Sud, Hospices Civils de Lyon, Pierre Benite, France
| | - I Coelho
- Hematology Department, Portuguese Institute of Oncology, Lisbon, Portugal
| | - S Bailly
- Hematology and Cell Therapy Department, Hôpital Estaing, CHU de Clermont-Ferrand, Clermont-Ferrand, France; Clermont Auvergne University, Clermont-Ferrand, France
| | | | - E Toussaint
- Hematology Department, CHU de Strasbourg, Strasbourg, France
| | | | - F Le Bras
- Hematology Department, CHU Henri Mondor, Creteil, France
| | - E Willems
- Hematology Department, CHU de Liège, Liège, Belgium
| | - E Tchernonog
- Hematology Department, CHU de Montpellier, Montpellier, France
| | - T Chalopin
- Hematology Department, CHU de Tours, Tours, France
| | - R Delarue
- Hematology Department, CHU Necker Enfants Malades, AP-HP, Paris, France
| | - R Gressin
- Hematology Department, CHU de Grenoble, Grenoble, France
| | - A Chauchet
- Hematology Department, CHU de Besançon, Besançon, France
| | - E Gyan
- Hematology Department, CHU de Tours, Tours, France
| | - G Cartron
- Hematology Department, CHU de Montpellier, Montpellier, France
| | - C Bonnet
- Hematology Department, CHU de Liège, Liège, Belgium
| | - C Haioun
- Hematology Department, CHU Henri Mondor, Creteil, France
| | - G Damaj
- Hematology Institute, CHU de Caen, Caen, France
| | - P Gaulard
- Hematology Department, CHU Henri Mondor, Creteil, France
| | - L Fornecker
- Hematology Department, CHU de Strasbourg, Strasbourg, France
| | - H Ghesquières
- Hematology Department, CHU Lyon Sud, Hospices Civils de Lyon, Pierre Benite, France
| | - O Tournilhac
- Hematology and Cell Therapy Department, Hôpital Estaing, CHU de Clermont-Ferrand, Clermont-Ferrand, France; Clermont Auvergne University, Clermont-Ferrand, France
| | - M Gomesda Silva
- Hematology Department, Portuguese Institute of Oncology, Lisbon, Portugal
| | - R Bouabdallah
- Hematology Department, Institut Paoli Calmette, Marseille, France
| | - G Salles
- Hematology Department, CHU Lyon Sud, Hospices Civils de Lyon, Pierre Benite, France; Claude Bernard Lyon 1 University, Lyon, France; Cancer Center of Lyon (CRCL), INSERM U1052 - CNRS UMR5286, Lyon, France
| | - E Bachy
- Hematology Department, CHU Lyon Sud, Hospices Civils de Lyon, Pierre Benite, France; Claude Bernard Lyon 1 University, Lyon, France; Cancer Center of Lyon (CRCL), INSERM U1052 - CNRS UMR5286, Lyon, France.
| |
Collapse
|
21
|
Yildiz H, Bailly S, Van Den Neste E, Yombi JC. Clinical Management of Relapsed/Refractory Hemophagocytic Lymphohistiocytosis in Adult Patients: A Review of Current Strategies and Emerging Therapies. Ther Clin Risk Manag 2021; 17:293-304. [PMID: 33888986 PMCID: PMC8056168 DOI: 10.2147/tcrm.s195538] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2021] [Accepted: 03/25/2021] [Indexed: 01/12/2023] Open
Abstract
Introduction Haemophagocytic lymphohistiocytosis (HLH) is a severe disorder with high mortality. The aim of this review is to update clinical management of relapsed/refractory HLH in adults, with a focus on current and new therapies. Methods We searched relevant articles in Embase and PUBMED with the MESH term “hemophagocytic lymphohistiocytosis; refractory; relapsing; adult.” Results One hundred eight papers were found; of these, 22 were retained for this review. The treatment of HLH in adult is based on the HLH-94 regimen. The response rate is lower than in pediatric patients, and 20–30% are refractory to this therapy. DEP regimen and allogenic hematopoietic stem cell transplantation (HSCT) are associated with complete response and partial response in 27% and 49.2%, respectively. However, many patients fail to achieve a stable condition before HSCT, and mortality is higher in them. New drugs have been developed, such as emapalumab, ruxolitinib, and alemtuzumab, and they may be used as bridges to the curative HSCT. They are relatively well tolerated and have few or mild side effects. With these agents, the rate of partial response ranges from 14.2% to 100%, while the rate of complete response is highly variable according to study and medication used. The number of patients who achieved HSCT ranged from 44.8% to 77%, with a survival rate of 55.9% to 100%. However, the populations in these studies are mainly composed of mixed-age patients (pediatric and adult patients), and studies including only adult patients are scarce. Conclusion Relapsed or refractory HLH in adult patients is associated with poor outcome, and consolidation with HSCT may be required in some cases. Mortality related to HSCT is mainly due to active HLH disease before HSCT and post HSCT complications. New drugs, such as empalumab, ruxolitinib, and alemtuzumab are interesting since these agents may be used as bridges to HSCT with increases in the numbers of patients proceeding to HSCT and survival rate.
Collapse
Affiliation(s)
- Halil Yildiz
- Departement of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint Luc, Bruxelles, Belgique
| | - Sarah Bailly
- Departement of Hematology, Cliniques Universitaires Saint Luc, Bruxelles, Belgique
| | - Eric Van Den Neste
- Departement of Hematology, Cliniques Universitaires Saint Luc, Bruxelles, Belgique
| | - Jean Cyr Yombi
- Departement of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint Luc, Bruxelles, Belgique
| |
Collapse
|
22
|
Damy T, Tamisier R, Davy J, Verbraecken J, Bailly S, Lavergne F, Palot A, Goutorbe F, Pépin J, D’ortho M. FACE: Phenotyping analysis of chronic heart failure (CHF) patients with sleep disordered breathing (SDB) indicated for adaptive servoventilation (ASV): 2-year follow-up results. Archives of Cardiovascular Diseases Supplements 2021. [DOI: 10.1016/j.acvdsp.2020.10.106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
23
|
Gunduz C, Basoglu OK, Kvamme JA, Verbraecken J, Anttalainen U, Marrone O, Steiropoulos P, Roisman G, Joppa P, Hein H, Trakada G, Hedner J, Grote L, Steiropoulos P, Verbraecken J, Petiet E, Trakada G, Montserrat J, Fietze I, Penzel T, Ondrej L, Rodenstein D, Masa J, Bouloukaki I, Schiza S, Kent B, McNicholas W, Ryan S, Riha R, Kvamme J, Hein H, Schulz R, Grote L, Hedner J, Zou D, Pépin J, Levy P, Bailly S, Lavie L, Lavie P, Basoglu O, Tasbakan M, Varoneckas G, Joppa P, Tkacova R, Staats R, Barbé F, Lombardi C, Parati G, Drummond M, van Zeller M, Bonsignore M, Marrone O, Petitjean M, Roisman G, Pretl M, Vitols A, Dogas Z, Galic T, Pataka A, Anttalainen U, Saaresranta T, Plywaczewski R, Sliwinski P, Bielicki P. Long-term positive airway pressure therapy is associated with reduced total cholesterol levels in patients with obstructive sleep apnea: data from the European Sleep Apnea Database (ESADA). Sleep Med 2020; 75:201-209. [DOI: 10.1016/j.sleep.2020.02.023] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/07/2019] [Revised: 02/02/2020] [Accepted: 02/25/2020] [Indexed: 12/18/2022]
|
24
|
Svedmyr S, Grote L, Zou D, Bailly S, Lombardi C, Ludka O, Bonsignore M, Schiza S, Kvamme J, Basoglu O, Verbraecken J, Hedner J. Blood pressure reduction following treatment with positive airway pressure in sleep apnea: data from the European Sleep Apnea Database. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2888] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Positive airway pressure (PAP) treatment modifies blood pressure (BP) in patients with obstructive sleep apnea (OSA). We aimed to explore which factors that influence the BP response to PAP therapy in the European Sleep Apnea Database (ESADA).
Methods
A total of 2662 OSA patients with PAP therapy ≥90 days were included in the analysis (74% male, age 55±11 years, body mass index 32.3±6.1 kg/m2, 47% hypertensives, apnea-hypopnea index 40±24 events/h, treatment duration 1.0±1.1 years, PAP compliance 5.2±1.9 h/day). Anthropometric data, co-medications and office BP were assessed at baseline and follow-up visit.
Results
Systolic and diastolic BP were modestly reduced after PAP therapy compared to baseline (133±17 vs. 134±17 mmHg, 78±11 vs. 81±11 mmHg, p<0.001, respectively). In a generalized linear model controlling for anthropometric, PAP compliance and follow-up time, severe OSA at baseline (β [95% CI] −3.2 [−5.1 to −1.3], p=0.001), hypertension status (−2.0 [−3.3 to −0.7], p=0.003), weight reduction >2 kg at follow up (−2.0 [−3.7 to −0.4], p=0.016), and use of auto-adjusted PAP (−1.3 [−2.5 to −0.02], p=0.046) were associated with a reduction of systolic BP at follow-up.
Conclusions
BP reduction following PAP treatment in patients with moderate to severe OSA was modest. We identified several predictors of a favorable BP response including the use of auto adjusted PAP. Our findings suggest that weight reduction strategies in addition to PAP treatment should be considered to obtain adequate BP control in OSA patients.
Funding Acknowledgement
Type of funding source: Other. Main funding source(s): European Respiratory Society funded Clinical Research Collaboration (2015-2020)
Collapse
Affiliation(s)
- S Svedmyr
- Institute of Medicine - Sahlgrenska Academy - University of Gothenburg, Gothenburg, Sweden
| | - L Grote
- Institute of Medicine - Sahlgrenska Academy - University of Gothenburg, Gothenburg, Sweden
| | - D Zou
- Institute of Medicine - Sahlgrenska Academy - University of Gothenburg, Gothenburg, Sweden
| | - S Bailly
- Grenoble Alpes University Hospital, Grenoble, France
| | - C Lombardi
- Istituto Auxologico Italiano, Milan, Italy
| | - O Ludka
- University Hospital Brno, Department of Cardiology, Brno, Czechia
| | | | - S Schiza
- University of Crete, Heraklion, Greece
| | | | | | | | - J Hedner
- Institute of Medicine - Sahlgrenska Academy - University of Gothenburg, Gothenburg, Sweden
| |
Collapse
|
25
|
Tamisier R, Damy T, Bailly S, Davy J, Goutorbe F, Lavergne F, Levy P, Palot A, Verbraecken J, D’ortho M, Pépin J. FACE: Prospective multicenter cohort addressing chronic heart failure patients with central sleep disorder breathing indicated for adaptive servo ventilation: patient baseline characteristics. Archives of Cardiovascular Diseases Supplements 2020. [DOI: 10.1016/j.acvdsp.2020.03.117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
26
|
Moury P, Zunarelli R, Bailly S, Durand Z, Behouche A, Garein M, Durand M, Verges S, Albaladejo P. Diaphragm thickening during va ecmo weaning in patients with cardiogenic shock. J Cardiothorac Vasc Anesth 2020. [DOI: 10.1053/j.jvca.2020.09.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
27
|
Revol B, Jullian-Desayes I, Bailly S, Tamisier R, Grillet Y, Sapène M, Joyeux-Faure M, Pépin J. Who may benefit from diuretics in obstructive sleep apnea? A propensity score-matched cohort study. Archives of Cardiovascular Diseases Supplements 2020. [DOI: 10.1016/j.acvdsp.2020.03.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
28
|
Philip P, Bailly S, Benmerad M, Micoulaud-Franchi JA, Grillet Y, Sapène M, Jullian-Desayes I, Joyeux-Faure M, Tamisier R, Pépin JL. Self-reported sleepiness and not the apnoea hypopnoea index is the best predictor of sleepiness-related accidents in obstructive sleep apnoea. Sci Rep 2020; 10:16267. [PMID: 33004829 PMCID: PMC7529742 DOI: 10.1038/s41598-020-72430-8] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2019] [Accepted: 07/13/2020] [Indexed: 11/19/2022] Open
Abstract
To evaluate the value of apnoea + hypopnoea index versus self-reported sleepiness at the wheel in anticipating the risk of sleepiness-related accidents in patients referred for obstructive sleep apnoea. A cross-sectional analysis of the French national obstructive sleep apnoea registry. 58,815 subjects referred for a suspicion of obstructive sleep apnoea were investigated by specific items addressing sleepiness at the wheel and sleepiness-related accidents. Apnoea + hypopnoea index was evaluated with a respiratory polygraphy or full polysomnography. Subjects had a median age of 55.6 years [45.3; 64.6], 65% were men, with a median apnoea + hypopnoea index of 22 [8; 39] events/h. Median Epworth sleepiness scale score was 9 [6; 13], 35% of the patients reported sleepiness at the wheel (n = 20,310), 8% (n = 4,588) reported a near-miss accident and 2% (n = 1,313) reported a sleepiness-related accident. Patients reporting sleepiness at the wheel whatever their obstructive sleep apnoea status and severity exhibited a tenfold higher risk of sleepiness-related accidents. In multivariate analysis, other predictors for sleepiness-related accidents were: male gender, ESS, history of previous near-miss accidents, restless leg syndrome/periodic leg movements, complaints of memory dysfunction and nocturnal sweating. Sleep apnoea per se was not an independent contributor. Self-reported sleepiness at the wheel is a better predictor of sleepiness-related traffic accidents than apnoea + hypopnoea index.
Collapse
Affiliation(s)
- P Philip
- SANPSY-USR 3413, SANPSY-CNRS, Bordeaux University, 33000, Bordeaux, France.
| | - S Bailly
- HP2 Laboratory, INSERM U1042, Grenoble Alpes University, Grenoble, France.,EFCR Laboratory, Grenoble Alps University Hospital, Pole Thorax et Vaisseaux, Grenoble, France
| | - M Benmerad
- HP2 Laboratory, INSERM U1042, Grenoble Alpes University, Grenoble, France.,EFCR Laboratory, Grenoble Alps University Hospital, Pole Thorax et Vaisseaux, Grenoble, France
| | | | - Y Grillet
- Private Practice Sleep and Respiratory Disease Centre, Valence, France
| | - M Sapène
- Private Practice Sleep and Respiratory Disease Centre, Nouvelle Clinique Bel Air, Bordeaux, France
| | - I Jullian-Desayes
- HP2 Laboratory, INSERM U1042, Grenoble Alpes University, Grenoble, France.,EFCR Laboratory, Grenoble Alps University Hospital, Pole Thorax et Vaisseaux, Grenoble, France
| | - M Joyeux-Faure
- HP2 Laboratory, INSERM U1042, Grenoble Alpes University, Grenoble, France.,EFCR Laboratory, Grenoble Alps University Hospital, Pole Thorax et Vaisseaux, Grenoble, France
| | - R Tamisier
- HP2 Laboratory, INSERM U1042, Grenoble Alpes University, Grenoble, France.,EFCR Laboratory, Grenoble Alps University Hospital, Pole Thorax et Vaisseaux, Grenoble, France
| | - J L Pépin
- HP2 Laboratory, INSERM U1042, Grenoble Alpes University, Grenoble, France.,EFCR Laboratory, Grenoble Alps University Hospital, Pole Thorax et Vaisseaux, Grenoble, France
| |
Collapse
|
29
|
Alexandre S, Baillieul S, Detante O, Yonnet F, Bailly S, Destors M, Guzun R, Pépin J, Tamisier R. Ischemic stroke location, sleep disordered breathing and sleep: Intermediate analysis of an observational prospective cohort. Archives of Cardiovascular Diseases Supplements 2020. [DOI: 10.1016/j.acvdsp.2020.03.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
30
|
Lefebvre M, Gross L, Ollivier R, Bailly S, Amisse C, Burel M, Gouraud M, Raffi F, Biron C, Coutherut J. Modalités et issue d’une campagne de vaccination optimisée en réponse à une épidémie de rougeole sur des bidonvilles. Med Mal Infect 2020. [DOI: 10.1016/j.medmal.2020.06.358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
31
|
Lattenist R, Yildiz H, De Greef J, Bailly S, Yombi JC. COVID-19 in Adult Patients with Hematological Disease: Analysis of Clinical Characteristics and Outcomes. Indian J Hematol Blood Transfus 2020; 37:181-185. [PMID: 32837052 PMCID: PMC7339791 DOI: 10.1007/s12288-020-01318-4] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2020] [Accepted: 07/01/2020] [Indexed: 12/13/2022] Open
Affiliation(s)
- R Lattenist
- Department of Internal Medicine and Infectious Diseases, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), 10 Av. Hippocrate, 1200 Brussels, Belgium
| | - H Yildiz
- Department of Internal Medicine and Infectious Diseases, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), 10 Av. Hippocrate, 1200 Brussels, Belgium
| | - J De Greef
- Department of Internal Medicine and Infectious Diseases, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), 10 Av. Hippocrate, 1200 Brussels, Belgium
| | - S Bailly
- Department of Hematology, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), 10 Av. Hippocrate, 1200 Brussels, Belgium
| | - J C Yombi
- Department of Internal Medicine and Infectious Diseases, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), 10 Av. Hippocrate, 1200 Brussels, Belgium
| |
Collapse
|
32
|
Dufour I, Raedemaeker J, Andreozzi F, Verstraete G, Bailly S, Delforge M, Storms P, Jacquy C, Van de Velde A, Mineur P, Lejeune M, Bauwens D, Van Obbergh F, Kentos A, Nguyen J, Fostier K, De Weweire A, Meuleman N, Vekemans MC. COVID-19, impact on myeloma patients. Ann Hematol 2020; 99:1947-1949. [PMID: 32577846 PMCID: PMC7311114 DOI: 10.1007/s00277-020-04147-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2020] [Accepted: 06/14/2020] [Indexed: 01/13/2023]
Affiliation(s)
- Inès Dufour
- Department of Hematology, Cliniques universitaires Saint-Luc, UCL, 1200, Brussels, Belgium
| | - Juliette Raedemaeker
- Department of Hematology, Cliniques universitaires Saint-Luc, UCL, 1200, Brussels, Belgium
| | - Fabio Andreozzi
- Department of Hematology, Cliniques universitaires Saint-Luc, UCL, 1200, Brussels, Belgium
| | - Géraldine Verstraete
- Department of Hematology, Cliniques universitaires Saint-Luc, UCL, 1200, Brussels, Belgium
| | - Sarah Bailly
- Department of Hematology, Cliniques universitaires Saint-Luc, UCL, 1200, Brussels, Belgium
| | | | - Pauline Storms
- Department of Hematology, Cliniques universitaires Saint-Luc, UCL, 1200, Brussels, Belgium
- University Hospital Leuven, Leuven, Belgium
| | | | | | | | - Marie Lejeune
- Centre Hospitalier Universitaire de Liège, Liège, Belgium
| | | | - Florence Van Obbergh
- Department of Hematology, Cliniques universitaires Saint-Luc, UCL, 1200, Brussels, Belgium
- Hôpital de Jolimont, Haine-Saint-Paul, Belgium
| | | | | | | | | | | | | |
Collapse
|
33
|
Flamand C, Bailly S, Fritzell C, Berthelot L, Vanhomwegen J, Salje H, Paireau J, Matheus S, Enfissi A, Fernandes-Pellerin S, Djossou F, Linares S, Carod JF, Kazanji M, Manuguerra JC, Cauchemez S, Rousset D. Impact of Zika Virus Emergence in French Guiana: A Large General Population Seroprevalence Survey. J Infect Dis 2020; 220:1915-1925. [PMID: 31418012 PMCID: PMC6834069 DOI: 10.1093/infdis/jiz396] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2019] [Accepted: 08/01/2019] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Since the identification of Zika virus (ZIKV) in Brazil in May 2015, the virus has spread throughout the Americas. However, ZIKV burden in the general population in affected countries remains unknown. METHODS We conducted a general population survey in the different communities of French Guiana through individual interviews and serologic survey during June-October 2017. All serum samples were tested for anti-ZIKV immunoglobulin G antibodies using a recombinant antigen-based SGERPAxMap microsphere immunoassay, and some of them were further evaluated through anti-ZIKV microneutralization tests. RESULTS The overall seroprevalence was estimated at 23.3% (95% confidence interval [CI], 20.9%-25.9%) among 2697 participants, varying from 0% to 45.6% according to municipalities. ZIKV circulated in a large majority of French Guiana but not in the most isolated forest areas. The proportion of reported symptomatic Zika infection was estimated at 25.5% (95% CI, 20.3%-31.4%) in individuals who tested positive for ZIKV. CONCLUSIONS This study described a large-scale representative ZIKV seroprevalence study in South America from the recent 2015-2016 Zika epidemic. Our findings reveal that the majority of the population remains susceptible to ZIKV, which could potentially allow future reintroductions of the virus.
Collapse
Affiliation(s)
| | | | | | - Léna Berthelot
- Arbovirus National Reference Center, Institut Pasteur, Cayenne, French Guiana
| | - Jessica Vanhomwegen
- Environment and Infectious Risks Unit, Unité Mixte de Recherche 2000, Centre National de la Recherche Scientifique, Paris, France
| | - Henrik Salje
- Mathematical Modelling of Infectious Diseases Unit, Unité Mixte de Recherche 2000, Centre National de la Recherche Scientifique, Paris, France
| | - Juliette Paireau
- Mathematical Modelling of Infectious Diseases Unit, Unité Mixte de Recherche 2000, Centre National de la Recherche Scientifique, Paris, France
| | - Séverine Matheus
- Arbovirus National Reference Center, Institut Pasteur, Cayenne, French Guiana.,Environment and Infectious Risks Unit, Unité Mixte de Recherche 2000, Centre National de la Recherche Scientifique, Paris, France
| | - Antoine Enfissi
- Arbovirus National Reference Center, Institut Pasteur, Cayenne, French Guiana
| | | | - Félix Djossou
- Infectious and Tropical Diseases Unit, Centre Hospitalier Andrée Rosemon, Cayenne, French Guiana
| | - Sébastien Linares
- Geographic Information and Knowledge Dissemination Unit, Direction de l'Environnement, de l'Aménagement et du Logement Guyane, Cayenne, French Guiana
| | - Jean-François Carod
- Medical Laboratory, Centre Hospitalier de l'Ouest Guyanais, Saint-Laurent du Maroni, French Guiana
| | | | - Jean-Claude Manuguerra
- Environment and Infectious Risks Unit, Unité Mixte de Recherche 2000, Centre National de la Recherche Scientifique, Paris, France
| | - Simon Cauchemez
- Mathematical Modelling of Infectious Diseases Unit, Unité Mixte de Recherche 2000, Centre National de la Recherche Scientifique, Paris, France
| | - Dominique Rousset
- Arbovirus National Reference Center, Institut Pasteur, Cayenne, French Guiana
| |
Collapse
|
34
|
Jolivet S, Lolom I, Bailly S, Bouadma L, Lortat-Jacob B, Montravers P, Armand-Lefevre L, Timsit JF, Lucet JC. Impact of colonization pressure on acquisition of extended-spectrum β-lactamase-producing Enterobacterales and meticillin-resistant Staphylococcus aureus in two intensive care units: a 19-year retrospective surveillance. J Hosp Infect 2020; 105:10-16. [PMID: 32092367 DOI: 10.1016/j.jhin.2020.02.012] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2019] [Accepted: 02/15/2020] [Indexed: 12/12/2022]
Abstract
BACKGROUND Colonization pressure is a risk factor for intensive care unit (ICU)-acquired multi-drug-resistant organisms (MDROs). AIM To measure the long-term respective impact of colonization pressure on ICU-acquired extended-spectrum β-lactamase-producing Enterobacterales (ESBL-PE) and meticillin-resistant Staphylococcus aureus (MRSA). METHODS All patients admitted to two ICUs (medical and surgical) between January 1997 and December 2015 were included in this retrospective observational study. Rectal and nasal surveillance cultures were obtained at admission and weekly thereafter. Contact precautions were applied for colonized or infected patients. Colonization pressure was defined as the ratio of the number of MDRO-positive patient-days (PDs) of each MDRO to the total number of PDs. Single-level negative binomial regression models were used to evaluate the incidence of weekly MDRO acquisition. FINDINGS Among the 23,423 patients included, 2327 (10.0%) and 1422 (6.1%) were colonized with ESBL-PE and MRSA, respectively, including 660 (2.8%) and 351 (1.5%) acquisitions. ESBL-PE acquisition increased from 0.51/1000 patient-exposed days (PEDs) in 1997 to 6.06/1000 PEDs in 2015 (P<0.001). In contrast, MRSA acquisition decreased steadily from 3.75 to 0.08/1000 PEDs (P<0.001). Controlling for period-level covariates, colonization pressure in the previous week was associated with MDRO acquisition for ESBL-PE (P<0.001 and P=0.04 for medical and surgical ICU, respectively), but not for MRSA (P=0.34 and P=0.37 for medical and surgical ICU, respectively). The increase in colonization pressure was significant above 100/1000 PDs for ESBL-PE. CONCLUSION Colonization pressure contributed to the increasing incidence of ESBL-PE but not MRSA. This study suggests that preventive control measures should be customized to MDROs.
Collapse
Affiliation(s)
- S Jolivet
- Infection Control Unit, Bichat University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; IAME, UMR 1137, INSERM, Université de Paris, Paris, France.
| | - I Lolom
- Infection Control Unit, Bichat University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - S Bailly
- University Grenoble Alpes, INSERM, CHU Grenoble Alpes, HP2, Grenoble, France
| | - L Bouadma
- IAME, UMR 1137, INSERM, Université de Paris, Paris, France; Medical Intensive Care Unit, Bichat University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - B Lortat-Jacob
- Department of Anaesthesiology and Intensive Care, Bichat University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - P Montravers
- Department of Anaesthesiology and Intensive Care, Bichat University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; INSERM UMR 1152, Paris, France
| | - L Armand-Lefevre
- IAME, UMR 1137, INSERM, Université de Paris, Paris, France; Bacteriology Laboratory, Bichat University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - J-F Timsit
- IAME, UMR 1137, INSERM, Université de Paris, Paris, France; Medical Intensive Care Unit, Bichat University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - J-C Lucet
- Infection Control Unit, Bichat University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; IAME, UMR 1137, INSERM, Université de Paris, Paris, France
| |
Collapse
|
35
|
Kohn M, Karras A, Zaidan M, Bénière C, de Fréminville JB, Laribi K, Perrin MC, Malphettes M, Le Calloch R, Anglaret B, Martiniuc J, Bailly S, Chevret S, Molina T, Thervet E, Thieblemont C. Lymphomas with kidney involvement: the French multicenter retrospective LyKID study. Leuk Lymphoma 2020; 61:887-895. [PMID: 32037948 DOI: 10.1080/10428194.2019.1697811] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
The LyKID study is a nationwide survey in France of lymphoma patients with renal involvement based on biopsy and/or imaging, to evaluate its impact on disease outcome and renal function. A total of 87 adult cases of B or T-cell lymphomas were retrospectively analyzed. Interstitial topography was observed in most of the kidney biopsies (54/66; 80%). Kidney failure (glomerular filtration rate <60 mL/min/1.73 m2) was present in 47% of patients and was associated with non-significantly different outcome. After lymphoma treatment, 44% of patients had persistent chronic kidney failure (CKF); kidney failure at diagnosis was the only parameter associated with CKF in multivariate analysis. DLBCL (diffuse large B-cell lymphomas) represented half of the series, with noticeably CNS (central neurological system) relapse in 17% patients, while fewer than one of two patients had received CNS prophylaxis. To our knowledge, the LyKID study represents the largest published non-autopsy lymphoma series with renal involvement.
Collapse
Affiliation(s)
- Milena Kohn
- Hémato-Oncologie, APHP, Hôpital Saint-Louis, Paris, France
| | - Alexandre Karras
- Néphrologie, APHP, Hôpital Européen Georges Pompidou, Paris, France
| | | | | | | | | | | | - Marion Malphettes
- Immuno-Pathologie Clinique, APHP, Hôpital Saint-Louis, Paris, France
| | - Ronan Le Calloch
- Service des Maladies du Sang, Médecine Interne, Maladies Infectieuses, CH de Quimper Cornouailles, Quimper, France
| | | | | | - Sarah Bailly
- Hématologie, Cliniques Universitaires Saint Luc Université catholique de Louvain, Bruxelles, Belgium
| | - Sylvie Chevret
- Biostatistiques, APHP, Hôpital Saint-Louis, Paris, France
| | | | - Eric Thervet
- Néphrologie, APHP, Hôpital Européen Georges Pompidou, Paris, France
| | | |
Collapse
|
36
|
Flamand C, Bailly S, Fritzell C, Fernandes Pellerin S, Toure A, Chateau N, Saout M, Linares S, Dubois F, Filleul L, Kazanji M. Vaccination coverage in the context of the emerging Yellow Fever threat in French Guiana. PLoS Negl Trop Dis 2019; 13:e0007661. [PMID: 31425507 PMCID: PMC6715233 DOI: 10.1371/journal.pntd.0007661] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2019] [Revised: 08/29/2019] [Accepted: 07/24/2019] [Indexed: 12/18/2022] Open
Abstract
Background French Guiana, a French overseas department located in South America between Brazil and Surinam, is the only European territory geographically located in the Amazonian forest complex and is considered endemic for yellow fever (YF). In the context of the emergent threat of YF in Latin America, we conducted a large household cross-sectional survey from June to October 2017 to estimate vaccination coverage in the population and to determine associations with sociodemographic and geographical characteristics. Methodology/Principal findings In total, 1,415 households and 2,697 individuals were included from the 22 municipalities of French Guiana. YF vaccination coverage was estimated at 95.0% (95% CI: 93.4–96.2) in the entire territory but was spatially heterogeneous, with the lowest levels estimated in the western part of the territory along the Surinamese cross-border region, particularly in children under 16 years who were not enrolled in school, immigrant adults and disadvantaged populations with low socioeconomic indexes. Conclusions/Significance Despite the good vaccination coverage against YF in the general population of French Guiana resulting from the compulsory nature of YF vaccination for residents and travelers, there is an urgent need to improve vaccination coverage in vulnerable populations living in the northwestern part of the territory to limit the risk of transmission in the context of the emerging YF threat in South America. Despite the relative rarity of YF and the significant number of infectious and tropical diseases in French Guiana, clinicians should adopt a high index of suspicion for YF, particularly in vulnerable and at-risk populations. Yellow fever (YF) is the most severe arbovirus to circulate in the Americas. French Guiana, a French overseas department located in South America between Brazil and Surinam, is the only European territory geographically located in the Amazonian forest complex and is considered endemic for YF. We conducted a large general population survey from June to October 2017 to estimate vaccination coverage in the population and to identify target vulnerable populations for catch-up vaccination strategies. In total, 1,415 households and 2,697 individuals were included from the 22 municipalities of French Guiana. YF vaccination coverage was estimated at 95.0% (95% CI: 93.4–96.2) in the entire territory but was spatially heterogeneous, with the lowest levels estimated in the western part of the territory along the Surinamese cross-border region, particularly in children under 16 years who were not enrolled in school, immigrant adults and disadvantaged groups of populations with low socioeconomic indexes. Our findings showed that vaccination campaigns should be prioritized and adapted to improve vaccination coverage among vulnerable populations living in the northwestern part of the territory to limit the risk of transmission in the context of the emerging YF threat in South America. Despite the relative rarity of YF and the significant number of infectious and tropical diseases in French Guiana, clinicians should adopt a high index of suspicion for YF, particularly in vulnerable and at-risk populations.
Collapse
Affiliation(s)
- Claude Flamand
- Epidemiology Unit, Institut Pasteur in French Guiana, Cayenne, French Guiana
- * E-mail:
| | - Sarah Bailly
- Epidemiology Unit, Institut Pasteur in French Guiana, Cayenne, French Guiana
| | - Camille Fritzell
- Epidemiology Unit, Institut Pasteur in French Guiana, Cayenne, French Guiana
| | | | - Alhassane Toure
- Epidemiology Unit, Institut Pasteur in French Guiana, Cayenne, French Guiana
| | - Naïssa Chateau
- Epidemiology Unit, Institut Pasteur in French Guiana, Cayenne, French Guiana
| | - Mona Saout
- Epidemiology Unit, Institut Pasteur in French Guiana, Cayenne, French Guiana
| | - Sébastien Linares
- Geographic Information and Knowledge Dissemination Unit, Direction de l’Environnement, de l’Aménagement et du logement Guyane, Cayenne, French Guiana
| | - Fabien Dubois
- Geographic Information and Knowledge Dissemination Unit, Direction de l’Environnement, de l’Aménagement et du logement Guyane, Cayenne, French Guiana
| | | | - Mirdad Kazanji
- Epidemiology Unit, Institut Pasteur in French Guiana, Cayenne, French Guiana
| |
Collapse
|
37
|
Morschhauser F, Le Gouill S, Feugier P, Bailly S, Nicolas-Virelizier E, Bijou F, Salles GA, Tilly H, Fruchart C, Van Eygen K, Snauwaert S, Bonnet C, Haioun C, Thieblemont C, Bouabdallah R, Wu KL, Canioni D, Meignin V, Cartron G, Houot R. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. Lancet Haematol 2019; 6:e429-e437. [PMID: 31296423 DOI: 10.1016/s2352-3026(19)30089-4] [Citation(s) in RCA: 33] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/13/2019] [Revised: 05/02/2019] [Accepted: 05/03/2019] [Indexed: 01/18/2023]
Abstract
BACKGROUND Lenalidomide plus rituximab is approved to treat patients with relapsed or refractory follicular lymphoma. Obinutuzumab has been shown to enhance antibody-dependent cellular cytotoxicity, phagocytosis, and direct B-cell killing better than rituximab. Our aim was to determine the activity and safety of lenalidomide plus obinutuzumab in previously treated patients with relapsed or refractory follicular lymphoma. METHODS In this multicentre, single-arm, phase 2 study, patients were enrolled from 24 Lymphoma Academic Research Organisation centres in France. Eligible patients (age ≥18 years) had histologically confirmed CD20-positive relapsed or refractory follicular lymphoma of WHO grade 1, 2, or 3a; an ECOG performance status of 0-2; and received at least one previous rituximab-containing therapy. Patients received oral lenalidomide (20 mg) plus intravenously infused obinutuzumab as induction therapy (1000 mg; six 28-day cycles), 1-year maintenance with lenalidomide (10 mg; 12 28-day cycles; days 2-22) plus obinutuzumab (1000 mg; alternate cycles), and 1-year maintenance with obinutuzumab (1000 mg; six 56-day cycles; day 1). The primary endpoint was the proportion of patients who achieved an overall response at induction end as per investigator assessment using the 1999 international working group criteria. The secondary endpoints were event-free survival, progression-free survival, overall survival, and safety. Analyses were per-protocol; the efficacy population included all patients who received at least one dose of both obinutuzumab and lenalidomide, and the safety population included all patients who received one dose of either investigational drug. The study is registered with ClinicalTrials.gov, number NCT01582776, and is ongoing but closed to accrual. FINDINGS Between June 11, 2014, and Dec 18, 2015, 89 patients were recruited and 86 patients were evaluable for efficacy and 88 for safety. Median follow-up was 2·6 years (IQR 2·2-2·8). 68 (79%) of 86 evaluable patients (95% CI 69-87) achieved an overall response at induction end, meeting the prespecified primary endpoint. At 2 years, event-free survival was 62% (95% CI 51-72), progression-free survival 65% (95% CI 54-74), duration of response 70% (95% CI 57-79), and overall survival 87% (95% CI 78-93). Complete response was achieved by 33 (38%, 95% CI 28-50) of 86 patients at induction end, and the proportion of patients achieving a best overall response was 70 (81%, 95% CI 72-89) and 72 (84%, 74-91) of 86 patients during induction and treatment, respectively. The most common adverse events were asthenia (n=54, 61%), neutropenia (n=38, 43%), bronchitis (n=36, 41%), diarrhoea (n=35, 40%), and muscle spasms (n=34, 39%). Neutropenia was the most common toxicity of grade 3 or more; four (5%) patients had febrile neutropenia. 57 serious adverse events were reported in 30 (34%) of 88 patients. The most common serious adverse events were basal cell carcinoma (n=5, 6%), febrile neutropenia (n=4, 5%), and infusion-related reaction (n=3, 3%). One patient died due to treatment-related febrile neutropenia. INTERPRETATION Our data shows that lenalidomide plus obinutuzumab is active in previously treated patients with relapsed or refractory follicular lymphoma, including those with early relapse, and has a manageable safety profile. Randomised trials of new immunomodulatory regimens, such as GALEN or using GALEN as a backbone, versus lenalidomide plus rituximab, are warranted. FUNDING Lymphoma Academic Research Organisation, and Celgene and Roche.
Collapse
Affiliation(s)
- Franck Morschhauser
- Université Lille, Centre Hospitalier Régional Universitaire de Lille, EA 7365, Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France.
| | - Steven Le Gouill
- Department of Haematology, Centre Hospitalier Universitaire Nantes, Nantes, France
| | - Pierre Feugier
- Centre Hospitalier Régional Universitaire de Nancy, Vandœuvre-lès-Nancy, France
| | - Sarah Bailly
- Cliniques Universitaires Saint-Luc, Bruxelles, Belgique
| | | | | | - Gilles A Salles
- Department of Haematology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Université de Lyon, Lyon, France
| | - Hervé Tilly
- Department of Haematology and INSERM 1245, Centre Henri Becquerel, University of Rouen, Rouen, France
| | - Christophe Fruchart
- Institut d'Hématologie de Basse Normandie, Centre Hospitalier Universitaire de Caen, France
| | | | | | - Christophe Bonnet
- Clinical Hematology, Centre Hospitalier Universitaire, University of Liège, Liège, Belgium
| | - Corinne Haioun
- Lymphoid Malignancies Unit, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Mondor, Créteil, France
| | - Catherine Thieblemont
- Hemato-Oncology, Hospital Saint-Louis, Assistance Publique-Hôpitaux de Paris, INSERM U 728, Institut Universitaire d'Hematologie, Paris, France
| | - Reda Bouabdallah
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France
| | - Ka Lung Wu
- Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerpen, Belgium
| | - Danielle Canioni
- Pathology Department, Hôpital Necker, Assistance Publique-Hôpitaux de Paris, Paris, France et Paris V Descartes University, Sorbonne-Paris-Cité, Paris, France
| | - Véronique Meignin
- Pathology Department, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris et Paris Cité Sorbonne Diderot 7 University, Paris, France
| | - Guillaume Cartron
- Centre Hospitalier Universitaire, UMR 5235, University of Montpellier, Montpellier, France
| | - Roch Houot
- Haematology Department, Centre Hospitalier Universitaire de Rennes, Rennes, France
| |
Collapse
|
38
|
Kaphan E, Germi R, Carré M, Bulabois C, Bailly S, Cahn J, Thiebaut-Bertrand A. Facteurs de risque de cystites à BK virus post allogreffe de cellules souches hématopoïétiques. Med Mal Infect 2019. [DOI: 10.1016/j.medmal.2019.04.098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
39
|
Bailly S, Daabek N, Jullian-Desayes I, Joyeux-Faure M, Sapene M, Grillet Y, Borel J, Tamisier R, Pepin J. Déterminants de la persistance d’événements résiduels chez les patients apnéiques traités par pression positive continue. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
40
|
Viglino D, Plazanet A, Bailly S, Benmerad M, Jullian-Desayes I, Tamisier R, Leroy V, Zarski J, Maignan M, Joyeux-Faure M, Pepin J. Impact de la stéatopathie métabolique sur la survenue d’événements cardiovasculaires et la mortalité des patients BPCO. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
41
|
Zelenka J, Svobodová E, Tarábek J, Hoskovcová I, Boguschová V, Bailly S, Sikorski M, Roithová J, Cibulka R. Combining Flavin Photocatalysis and Organocatalysis: Metal-Free Aerobic Oxidation of Unactivated Benzylic Substrates. Org Lett 2018; 21:114-119. [PMID: 30582822 DOI: 10.1021/acs.orglett.8b03547] [Citation(s) in RCA: 64] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
We report a system with ethylene-bridged flavinium salt 2b which catalyzes the aerobic oxidation of toluenes and benzyl alcohols with high oxidation potential ( Eox > +2.5 V vs SCE) to give the corresponding benzoic acids under visible light irradiation. This is caused by the high oxidizing power of excited 2b ( E(2b*) = +2.67 V vs SCE) involved in photooxidation and by the accompanying dark organocatalytic oxygenation provided by the in situ formed flavin hydroperoxide 2b-OOH.
Collapse
Affiliation(s)
- Jan Zelenka
- Institute for Molecules and Materials , Radboud University , Heyendaalseweg 135 , 6525 AJ Nijmegen , The Netherlands
| | | | - Ján Tarábek
- Institute of Organic Chemistry and Biochemistry , Academy of Science of the Czech Republic , Flemingovo náměstí 542/2 , 16610 Prague , Czech Republic
| | | | | | | | - Marek Sikorski
- Faculty of Chemistry ; Adam Mickiewicz University in Poznan , Umultowska 89b , 61614 Poznan , Poland
| | - Jana Roithová
- Institute for Molecules and Materials , Radboud University , Heyendaalseweg 135 , 6525 AJ Nijmegen , The Netherlands
| | | |
Collapse
|
42
|
Truche AS, Ragey SP, Souweine B, Bailly S, Zafrani L, Bouadma L, Clec'h C, Garrouste-Orgeas M, Lacave G, Schwebel C, Guebre-Egziabher F, Adrie C, Dumenil AS, Zaoui P, Argaud L, Jamali S, Goldran Toledano D, Marcotte G, Timsit JF, Darmon M. ICU survival and need of renal replacement therapy with respect to AKI duration in critically ill patients. Ann Intensive Care 2018; 8:127. [PMID: 30560526 PMCID: PMC6297118 DOI: 10.1186/s13613-018-0467-6] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2018] [Accepted: 11/30/2018] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Transient and persistent acute kidney injury (AKI) could share similar physiopathological mechanisms. The objective of our study was to assess prognostic impact of AKI duration on ICU mortality. DESIGN Retrospective analysis of a prospective database via cause-specific model, with 28-day ICU mortality as primary end point, considering discharge alive as a competing event and taking into account time-dependent nature of renal recovery. Renal recovery was defined as a decrease of at least one KDIGO class compared to the previous day. SETTING 23 French ICUs. PATIENTS Patients of a French multicentric observational cohort were included if they suffered from AKI at ICU admission between 1996 and 2015. INTERVENTION None. RESULTS A total of 5242 patients were included. Initial severity according to KDIGO creatinine definition was AKI stage 1 for 2458 patients (46.89%), AKI stage 2 for 1181 (22.53%) and AKI stage 3 for 1603 (30.58%). Crude 28-day ICU mortality according to AKI severity was 22.74% (n = 559), 27.69% (n = 327) and 26.26% (n = 421), respectively. Renal recovery was experienced by 3085 patients (58.85%), and its rate was significantly different between AKI severity stages (P < 0.01). Twenty-eight-day ICU mortality was independently lower in patients experiencing renal recovery [CSHR 0.54 (95% CI 0.46-0.63), P < 0.01]. Lastly, RRT requirement was strongly associated with persistent AKI whichever threshold was chosen between day 2 and 7 to delineate transient from persistent AKI. CONCLUSIONS Short-term renal recovery, according to several definitions, was independently associated with higher mortality and RRT requirement. Moreover, distinction between transient and persistent AKI is consequently a clinically relevant surrogate outcome variable for diagnostic testing in critically ill patients.
Collapse
Affiliation(s)
- A S Truche
- UMR 1137 - IAME Team 5 - DeSCID : Decision SCiences in Infectious Diseases, Control and Care, Inserm/Paris Diderot University, Sorbonne Paris Cité, Paris, France
- Medical Intensive Care Unit, Grenoble University Hospital, Grenoble 1 University, U823, La Tronche, France
- Nephrology Dialysis Renal Transplantation, Grenoble University Hospital, La Tronche, France
| | - S Perinel Ragey
- Medical Intensive Care Unit, Croix Rousse Hospital, Lyon University Hospital, Lyon, France
| | - B Souweine
- Medical Intensive Care Unit, Gabriel Montpied University Hospital, Clermont-Ferrand, France
| | - S Bailly
- UMR 1137 - IAME Team 5 - DeSCID : Decision SCiences in Infectious Diseases, Control and Care, Inserm/Paris Diderot University, Sorbonne Paris Cité, Paris, France
- Medical Intensive Care Unit, Grenoble University Hospital, Grenoble 1 University, U823, La Tronche, France
| | - L Zafrani
- Medical Intensive Care Unit, AP-HP, Saint Louis Hospital, Paris, France
- Medicine University, Paris 7 University, Paris, France
| | - L Bouadma
- Medical and Infectious Diseases Intensive Care Unit, AP-HP, Bichat Hospital, Paris Diderot University, 75018, Paris, France
| | - C Clec'h
- Intensive Care Unit, AP-HP, Avicenne Hospital, Paris, France
- Medicine University, Paris 13 University, Bobigny, France
| | - M Garrouste-Orgeas
- Intensive Care Unit, Saint Joseph Hospital Network, Paris, France
- Medicine University, Paris Descartes University, Sorbonne Cite, Paris, France
| | - G Lacave
- Medical Intensive Care Unit, André Mignot Hospital, Versailles, France
| | - C Schwebel
- Medical Intensive Care Unit, Grenoble University Hospital, Grenoble 1 University, U823, La Tronche, France
| | - F Guebre-Egziabher
- Nephrology Dialysis Renal Transplantation, Grenoble University Hospital, La Tronche, France
| | - C Adrie
- Physiology Department, Cochin University Hospital, Assistance Publique, Hôpitaux de Paris (AP-HP), Paris Descartes University des, Sorbonne Cite, Paris, France
| | - A S Dumenil
- Medical-Surgical Intensive Care Unit, AP-HP, Antoine Béclère University Hospital, Clamart, France
| | - Ph Zaoui
- Nephrology Dialysis Renal Transplantation, Grenoble University Hospital, La Tronche, France
| | - L Argaud
- Medical Intensive Care Unit, Edouard Herriot University Hospital, Lyon, France
| | - S Jamali
- Critical Care Medicine Unit, Dourdan Hospital, Dourdan, France
| | | | - G Marcotte
- Surgical ICU, Edouard Herriot University Hospital, Lyon, France
| | - J F Timsit
- UMR 1137 - IAME Team 5 - DeSCID : Decision SCiences in Infectious Diseases, Control and Care, Inserm/Paris Diderot University, Sorbonne Paris Cité, Paris, France
- Medical and Infectious Diseases Intensive Care Unit, AP-HP, Bichat Hospital, Paris Diderot University, 75018, Paris, France
| | - M Darmon
- Medical Intensive Care Unit, AP-HP, Saint Louis Hospital, Paris, France.
- Medicine University, Paris 7 University, Paris, France.
- ECSTRA Team, Biostatistics and Clinical Epidemiology, UMR 1153 (Center of Epidemiology and Biostatistics Sorbonne Paris Cité, CRESS), INSERM, Paris, France.
| |
Collapse
|
43
|
Lheureux L, Bailly S, Kammerer M. Intoxication par les mycotoxines tremorgènes chez le chien. Toxicologie Analytique et Clinique 2018. [DOI: 10.1016/j.toxac.2018.07.083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
44
|
Philip P, Bailly S, Benmerad M, Micoulaud-Franchi J, Grillet Y, Sapene M, Tamisier R, Pepin J. 0586 Self Reported Sleepiness At The Wheel Versus Apnea Hypopnea Index To Predict Sleep Related Accidental Risk Of Patients Suspected Obstructive Sleep Apnea Syndrome. Sleep 2018. [DOI: 10.1093/sleep/zsy061.585] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- P Philip
- SANPSY-USR 3413, SANPSY-CNRS, FRANCE
| | - S Bailly
- AME UMR 1137 Inserm Université Paris Diderot, F-75018, Paris, France, CHU de Grenoble, FRANCE
| | - M Benmerad
- Hypoxia-pathophysiology Laboratory - INSERM U1042, Grenoble Alps University Hospital, Université Grenoble Alpes, Grenoble, France, CHU de Grenoble, FRANCE
| | | | - Y Grillet
- Pneumologist, Private Clinic, Valence, France, Private Clinic, FRANCE
| | - M Sapene
- Pneumologist, Private Clinic, Bordeaux, France, Private Clinic, FRANCE
| | - R Tamisier
- Univ. Grenoble Alpes, HP2; Inserm, U1042, Grenoble, France, CHU de Grenoble, FRANCE
| | - J Pepin
- Univ. Grenoble Alpes, HP2; Inserm, U1042, Grenoble, France, CHU de Grenoble, FRANCE
| | | |
Collapse
|
45
|
Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E, Lancesseur C, Le Bras F, Willems E, Tchernonog E, Chalopin T, Delarue R, Gressin R, Chauchet A, Gyan E, Cartron G, Bonnet C, Haioun C, Damaj G, Gaulard P, Fornecker L, Ghesquières H, Tournilhac O, da Silva MG, Bouabdallah R, Salles G, Bachy E. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol 2018; 29:715-723. [DOI: 10.1093/annonc/mdx787] [Citation(s) in RCA: 69] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
46
|
Van Den Neste E, André M, Gastinne T, Stamatoullas A, Haioun C, Belhabri A, Reman O, Casasnovas O, Ghesquieres H, Verhoef G, Claessen MJ, Poirel HA, Copin MC, Dubois R, Vandenberghe P, Stoian IA, Cottereau AS, Bailly S, Knoops L, Morschhauser F. A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma. Haematologica 2018; 103:840-848. [PMID: 29351986 PMCID: PMC5927969 DOI: 10.3324/haematol.2017.180554] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2017] [Accepted: 01/10/2018] [Indexed: 12/31/2022] Open
Abstract
JAK2 constitutive activation/overexpression is common in classical Hodgkin lymphoma, and several cytokines stimulate Hodgkin lymphoma cells by recognizing JAK1-/JAK2-bound receptors. JAK blockade may thus be therapeutically beneficial in Hodgkin lymphoma. In this phase II study we assessed the safety and efficacy of ruxolitinib, an oral JAK1/2 inhibitor, in patients with relapsed/refractory Hodgkin lymphoma. The primary objective was overall response rate according to the International Harmonization Project 2007 criteria. Thirty-three patients with advanced disease (median number of prior lines of treatment: 5; refractory: 82%) were included; nine (27.3%) received at least six cycles of ruxolitinib and six (18.2%) received more than six cycles. The overall response rate after six cycles was 9.4% (3/32 patients). All three responders had partial responses; another 11 patients had transient stable disease. Best overall response rate was 18.8% (6/32 patients). Rapid alleviation of B-symptoms was common. The median duration of response was 7.7 months, median progression-free survival 3.5 months (95% CI: 1.9–4.6), and the median overall survival 27.1 months (95% CI: 14.4–27.1). Forty adverse events were reported in 14/33 patients (42.4%). One event led to treatment discontinuation, while 87.5% of patients recovered without sequelae. Twenty-five adverse events were grade 3 or higher. These events were mostly anemia (n=11), all considered related to ruxolitinib. Other main causes of grade 3 or higher adverse events included lymphopenia and infections. Of note, no cases of grade 4 neutropenia or thrombocytopenia were observed. Ruxolitinib shows signs of activity, albeit short-lived, beyond a simple anti-inflammatory effect. Its limited toxicity suggests that it has the potential to be combined with other therapeutic modalities. ClinicalTrials.gov: NCT01877005
Collapse
Affiliation(s)
- Eric Van Den Neste
- Department of Hematology, Cliniques Universitaires Saint-Luc, UCL Brussels, Belgium
| | - Marc André
- Hematology Department, CHU UCL Namur, Yvoir, Belgium
| | | | | | - Corinne Haioun
- Lymphoid Malignancies Unit, AP-HP, Groupe Hospitalier Mondor, Créteil, France
| | - Amine Belhabri
- Onco-hematology, Centre Leon Berard, University Claude Bernard Lyon 1, France
| | - Oumedaly Reman
- Hematology, Centre Hospitalier Universitaire, Caen, France
| | | | - Hervé Ghesquieres
- Hospices Civils de Lyon, Université Claude Bernard, Centre Hospitalier Lyon-Sud, Pierre Bénite, France
| | - Gregor Verhoef
- Department of Hematology, University Hospitals Leuven, Belgium
| | | | - Hélène A Poirel
- Center for Human Genetics, Cliniques universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
| | | | | | | | | | | | - Sarah Bailly
- Department of Hematology, Cliniques Universitaires Saint-Luc, UCL Brussels, Belgium
| | - Laurent Knoops
- Cliniques Universitaires Saint-Luc and de Duve Institute, Université Catholique de Louvain, Brussels, Belgium
| | | |
Collapse
|
47
|
Wawrzyniak V, Allemand P, Bailly S, Lejot J, Piégay H. Coupling LiDAR and thermal imagery to model the effects of riparian vegetation shade and groundwater inputs on summer river temperature. Sci Total Environ 2017; 592:616-626. [PMID: 28318696 DOI: 10.1016/j.scitotenv.2017.03.019] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/25/2017] [Revised: 03/02/2017] [Accepted: 03/02/2017] [Indexed: 06/06/2023]
Abstract
In the context of global warming, it is important to understand the drivers controlling river temperature in order to mitigate temperature increases. A modeling approach can be useful for quantifying the respective importance of the different drivers, notably groundwater inputs and riparian shading which are potentially critical for reducing summer temperature. In this study, we use a one-dimensional deterministic model to predict summer water temperature at an hourly time step over a 21km reach of the lower Ain River (France). This sinuous gravel-bed river undergoes summer temperature increase with potential impacts on salmonid populations. The model considers heat fluxes at the water-air interface, attenuation of solar radiation by riparian forest, groundwater inputs and hydraulic characteristics of the river. Modeling is performed over two periods of five days during the summers 2010 and 2011. River properties are obtained from hydraulic modeling based on cross-section profiles and water level surveys. We model shadows of the vegetation on the river surface using LiDAR data. Groundwater inputs are determined using airborne thermal infrared (TIR) images and hydrological data. Results indicate that vegetation and groundwater inputs can mitigate high water temperatures during summer. Riparian shading effect is fairly similar between the two periods (-0.26±0.12°C and -0.31±0.18°C). Groundwater input cooling is variable between the two studied periods: when groundwater discharge represents 16% of the river discharge, it cools the river down by 0.68±0.13°C while the effect is very low (0.11±0.01°C) when the groundwater discharge contributes only 2% to the discharge. The effect of shading varies through the day: low in the morning and high during the afternoon and the evening whereas those induced by groundwater inputs is more constant through the day. Overall, the effect of riparian vegetation and groundwater inputs represents about 10% in 2010 and 24% in 2011 of water temperature diurnal amplitudes.
Collapse
Affiliation(s)
- Vincent Wawrzyniak
- EVS, CNRS-UMR 5600, Université de Lyon, ENS de Lyon, Plateforme ISIG. 15, Parvis René Descartes, BP 7000, F69342 Lyon Cedex 07, France; ThéMA, CNRS-UMR 6049, Université Bourgogne - Franche-Comté, 32 rue Mégevand, F25030 Besançon Cedex, France.
| | - Pascal Allemand
- LGLTPE, CNRS-UMR 5276, Université de Lyon, Université Lyon 1, ENS de Lyon, 2 rue Raphaël Dubois, F69622 Villeurbanne Cedex, France
| | - Sarah Bailly
- EVS, CNRS-UMR 5600, Université de Lyon. Université Lyon 2, Campus Porte des Alpes, 5 avenue Pierre Mendès France, F69500 Bron, France
| | - Jérôme Lejot
- EVS, CNRS-UMR 5600, Université de Lyon. Université Lyon 2, Campus Porte des Alpes, 5 avenue Pierre Mendès France, F69500 Bron, France
| | - Hervé Piégay
- EVS, CNRS-UMR 5600, Université de Lyon, ENS de Lyon, Plateforme ISIG. 15, Parvis René Descartes, BP 7000, F69342 Lyon Cedex 07, France
| |
Collapse
|
48
|
Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E, Lancesseur C, Lebras F, Willems E, Tchernonog E, Delarue R, Gressin R, Chauchet A, Gyan E, Cartron G, Bonnet C, Haioun C, Damaj G, Gaulard P, Fornecker L, Ghesquieres H, Tournilhac O, Gomes Da Silva M, Bouabdallah R, Salles G, Bachy E. ROLE OF UP-FRONT AUTOLOGOUS STEM CELL TRANSPLANTATION IN PERIPHERAL T-CELL LYMPHOMAS: a PROPENSITY SCORE MATCHING ANALYSIS OF PATIENTS FROM LYSA CENTERS. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_64] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- G. Fossard
- Hematology; Centre Hospitalier Lyon Sud; Pierre Bénite France
| | - F. Broussais
- Hematology; Centre Hospitalier Lyon Sud; Pierre Bénite France
| | - I. Coelho
- Hematology; Portuguese Institute of Oncology; Lisbon Portugal
| | - S. Bailly
- Hematology and Cell Therapy Department; Hôpital Estaing; Clermont-Ferrand France
| | | | - E. Toussaint
- Hematology; CHU de Strasbourg; Strasbourg France
| | | | - F. Lebras
- Lymphoid malignancies Unit; CHU Henri Mondor; Créteil France
| | | | | | - R. Delarue
- Hematology; CHU Necker Enfants Malades; Paris France
| | - R. Gressin
- Hematology; CHU Grenoble; Grenoble France
| | | | - E. Gyan
- Hematology; CHU de Tours; Tours France
| | - G. Cartron
- Hematology; CHU de Montpellier; Montpellier France
| | - C. Bonnet
- Hematology; CHU Liège; Liège Belgium
| | - C. Haioun
- Lymphoid malignancies Unit; CHU Henri Mondor; Créteil France
| | - G. Damaj
- Hematology; CHU de Caen; Caen France
| | - P. Gaulard
- Hematology; CHU Henri Mondor; Créteil France
| | - L. Fornecker
- Hematology; CHU de Strasbourg; Strasbourg France
| | - H. Ghesquieres
- Hematology; Centre Hospitalier Lyon Sud; Pierre Bénite France
| | - O. Tournilhac
- Hematology and Cell Therapy Department; Hôpital Estaing; Clermont-Ferrand France
| | | | | | - G. Salles
- Hematology; Centre Hospitalier Lyon Sud; Pierre Bénite France
| | - E. Bachy
- Hematology; Centre Hospitalier Lyon Sud; Pierre Bénite France
| |
Collapse
|
49
|
Montravers P, Perrigault PF, Timsit JF, Mira JP, Lortholary O, Leroy O, Gangneux JP, Guillemot D, Bensoussan C, Bailly S, Azoulay E, Constantin JM, Dupont H. Antifungal therapy for patients with proven or suspected Candida peritonitis: Amarcand2, a prospective cohort study in French intensive care units. Clin Microbiol Infect 2016; 23:117.e1-117.e8. [PMID: 27746395 DOI: 10.1016/j.cmi.2016.10.001] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2016] [Revised: 08/04/2016] [Accepted: 10/05/2016] [Indexed: 12/31/2022]
Abstract
OBJECTIVE The clinical characteristics and prognosis of patients treated for Candida peritonitis (CP) were compared according to the type of systemic antifungal therapy (SAT), empiric (EAF) or targeted (TAF) therapies, and the final diagnosis of infection. METHODS Patients in intensive care units (ICU) treated for CP were selected among the AmarCAND2 cohort, to compare patients receiving EAF for unconfirmed suspicion of CP (EAF/nonCP), to those with suspected secondarily confirmed CP (EAF/CP), or with primarily proven CP receiving TAF. RESULTS In all, 279 patients were evaluated (43.4% EAF/nonCP, 29.7% EAF/CP and 25.8% TAF patients). At SAT initiation, the severity of illness was similar among EAF/nonCP and EAF/CP patients, lower among TAF patients (median Simplified Acute Physiology Score II (SAPS II) 49 and 51 versus 35, respectively; p 0.001). Candida albicans was involved in 67%, Candida glabrata in 15.6%. All strains were susceptible to echinocandin; 84% to fluconazole. Echinocandin was administered to 51.2% EAF/nonCP, 49% EAF/CP and 40% TAF patients. At day 28, 72%, 76% and 75% of EAF/nonCP, EAF/CP and TAF patients, respectively, were alive. An increased mortality was observed in patients with a Sequential Organ Failure Assessment (SOFA) score <7 if SAT was delayed by ≥6 days (p 0.04). Healthcare-associated CP (OR 3.82, 95% CI 1.52-9.64, p 0.004), SOFA ≥8 at ICU admission (OR 2.61, 95% CI 1.08-6.34; p 0.03), and SAPS II ≥45 at SAT initiation (OR 5.08, 95% CI 1.04-12.67; p 0.001) impacted the 28-day mortality. CONCLUSIONS In summary, only 56.6% of ICU patients receiving SAT had CP. Most strains were susceptible to SAT. A similar 28-day mortality rate was observed among groups; the late administration of SAT significantly worsened the prognosis of patients with less severe CP.
Collapse
Affiliation(s)
- P Montravers
- Paris Diderot Sorbonne Cite University, and Anesthesiology and Critical Care Medicine, Bichat-Claude Bernard University Hospital, HUPNSV, AP-HP, Paris, France.
| | - P F Perrigault
- Medical-surgical ICU, Montpellier University Hospital, Montpellier, France
| | - J F Timsit
- Medical ICU, Paris Diderot University, and Bichat University Hospital, HUPNVS, AP-HP, Paris, France
| | - J P Mira
- Medical ICU, Cochin University Hospital, HUPC, AP-HP, and Paris Descartes, Sorbonne Paris Cité University, Paris, France
| | - O Lortholary
- University Paris Descartes, Necker Pasteur Centre for Infectious Diseases, HUNEM, AP-HP, IHU Imagine, Paris, France; Pasteur Institute, National Reference Centre for Invasive Mycoses and Antifungals, CNRS URA3012, Paris, France
| | - O Leroy
- Medical ICU, Chatilliez Hospital, Tourcoing, France
| | - J P Gangneux
- Mycology, Rennes University Hospital, Rennes, France
| | - D Guillemot
- Inserm UMR 1181 « Biostatistics, Biomathematics, Pharmaco-epidemiology and Infectious Diseases » (B2PHI), F-75015 Paris, France
| | - C Bensoussan
- Medical Affairs, Therapy Area Hospital, MSD France, Courbevoie, France
| | - S Bailly
- Inserm UMR 1137 - IAME Team 5 - DeSCID: Decision SCiences in Infectious Diseases, Control and Care INSERM/Paris Diderot, Sorbonne Paris Cité University, Paris, France
| | - E Azoulay
- Medical ICU, Saint-Louis University Hospital, HUSLLFW, AP-HP, Paris, France
| | - J M Constantin
- Perioperative Medicine Department, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
| | - H Dupont
- Surgical ICU, Amiens University Hospital, Amiens, France
| |
Collapse
|
50
|
Gallien B, Bailly S, Duffar T. Comparative study of dislocation density characterizations on silicon. Crystal Research and Technology 2016. [DOI: 10.1002/crat.201600224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- B. Gallien
- Univ. Grenoble-alpes, CNRS, SIMAP; F-38402 Saint Martin d'Hères France
- CEA-INES, 50 Avenue du Lac Léman; F-73375 Le Bourget du Lac
| | - S. Bailly
- CEA-INES, 50 Avenue du Lac Léman; F-73375 Le Bourget du Lac
| | - T. Duffar
- Univ. Grenoble-alpes, CNRS, SIMAP; F-38402 Saint Martin d'Hères France
| |
Collapse
|